WO2009016253A2 - Cyanomethyl substituted n-acyl tryptamines - Google Patents

Cyanomethyl substituted n-acyl tryptamines Download PDF

Info

Publication number
WO2009016253A2
WO2009016253A2 PCT/EP2008/060123 EP2008060123W WO2009016253A2 WO 2009016253 A2 WO2009016253 A2 WO 2009016253A2 EP 2008060123 W EP2008060123 W EP 2008060123W WO 2009016253 A2 WO2009016253 A2 WO 2009016253A2
Authority
WO
WIPO (PCT)
Prior art keywords
cyano
indol
ethyl
trifluoromethoxy
amide
Prior art date
Application number
PCT/EP2008/060123
Other languages
French (fr)
Other versions
WO2009016253A3 (en
Inventor
Lars Wortmann
Marcus Koppitz
Hans-Peter Muhn
Thomas Frenzel
Florian Peter Liesener
Anna Katharina Schrey
Ronald KÜHNE
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of WO2009016253A2 publication Critical patent/WO2009016253A2/en
Publication of WO2009016253A3 publication Critical patent/WO2009016253A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel cyanomethyl substituted N-acyl tryptamines with FSH-receptor antagonist activity.
  • the present invention also relates to a process for their preparation, pharmaceutical compositions comprising the compounds according to the invention, and the use thereof for fertility control in men or women, for the treatment and/or prevention of osteoporosis.
  • Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are together responsible for the control of male and female fertility and of the production of sex steroids.
  • FSH controls the early ripening of ovarian primary follicles and the biosynthesis of sex steroids.
  • advanced stage of differentiation preantral follicles
  • LH becomes increasingly important for further development of the follicles until ovulation occurs.
  • FSH is primarily responsible for the differentiation and stimulation of Sertoli cells. Their function consists of assisting spermatogenesis on many levels.
  • LH is primarily responsible for stimulating the Leydig cells and thus androgen production.
  • FSH, LH and TSH (thyrotropic hormone) together form the group of glycoprotein hormones which are formed in the pituitary and are secreted from there. Whereas the alpha subunit is common to the three hormones, their specificity of action is determined by the beta chain which is unique in each case.
  • the molecular weight of FSH including the sugar portion is about 30 kD.
  • FSH and the other glycoprotein hormones act specifically via their selectively expressed G protein-coupled receptor (GPCR).
  • FSH stimulates, through binding to its receptor, the association thereof with a stimulating G protein (G s ) which is thereby stimulated to hydrolyse guanosine triphosphate (GTP) and to activate the membrane-associated adenylate cyclase.
  • G s stimulating G protein
  • GTP hydrolyse guanosine triphosphate
  • Cyclic adenosine monophosphate (cAMP) is accordingly an important and readily quantifiable secondary messenger substance of FSH (G. Vassart, L. Pardo, S. Costagliola, Trends Biochem. Sci. 2004, 29, 119-126).
  • FSH farnesoid spermatogenesis
  • spermatogenesis such as the proliferation of spermatogonia, the antiapoptotic effect on spermatogonia and spermatocytes and the stimulation of sperm maturation including motility thereof.
  • the following arguments are also in favour of the FSH receptor as target for male fertility control:
  • the FSH receptor is exclusively expressed on Sertoli cells (high specificity). 2. Contraceptive vaccination against FSH beta chain or the FSH receptor induces infertility in male primates (N. R. Mougdal, M. Jeyakumar, H. N. Krishnamurthy, S.
  • FSH antagonists are expected to be suitable for spermatogenesis inhibition (prevention) in men. Moreover, a suitable FSH antagonist may just as well lead to infertility in women, because it suppresses follicle ripening and thus also ovulation.
  • the skilled person expects advantages from non- peptidergic FSH agonists when used to promote fertility in women (stimulation of follicle ripening).
  • FSH or FSH agonists in male infertility, but specific indications are also conceivable in this connection. New findings demonstrate that there is also a direct effect of FSH on cells of bone metabolism.
  • osteoclasts There are two fundamentally different cell types in bones: osteoclasts and osteoblasts. While osteoclasts play a central role in bone resorption (breakdown of bone), osteoblasts simulate bone density (anabolic effect). FSH receptors have been detected in osteoclasts but not in osteoblasts. In vitro, FSH stimulates bone resorption by mouse osteoclasts ( Li Sun et al. Cell 2006; 125: 247-60). A clinical correlation between the serum FSH level and low bone density has been observed in postmenopausal women (Devleta et al, J. Bone Miner. Metab. 2004, 22: 360- 4).
  • FSH stimulates loss of bone mass
  • FSH antagonists will display an antiresorptive effect on bone and are therefore suitable for the therapy and/or prevention of peri- and postmenopausal loss of bone mass and osteoporosis.
  • FSH receptor modulators are compounds that have a mixed profile of both FSH receptor antagonistic and FSH receptor agonistic properties. FSH receptor modulators of various compound classes of low molecular weight, have been reported on recently. FSH receptor modulators are disclosed in WO 2004/056779, WO 2004/056780; J. Med. Chem. 2005, 48, 1697 [tetrahydroquinolines]; WO 02/70493, Bioorg. Med. Chem. Lett. 2004, 14, 1713 and 1717 [diketopiperazines]; and WO 01/47875 [sulphonamides]. FSH receptor agonists are disclosed in WO 02/09706; J. Comb. Chem.
  • FSH receptor antagonists are disclosed in WO 03/004028 [tetrahydroquinolines], WO 02/09705 [thiazolidinones], WO 00/58277, Bioorg. Med. Chem. 2002, 10, 639 [sulphonic acids]; WO 00/58276, Endocr. 2002, 143, 3822; Synth. Comm.
  • WO 2007/017289 is considered to be the closest prior art.
  • R1 is hydrogen, fluorine or d-C 6 -alkyl; where the hydrocarbon chains therein may optionally be substituted one or more times by fluorine;
  • R2 is hydrogen, halogen, nitro, amino, cyano, d-C 6 -alkyl, C 2 -C 6 -alkenyl or C 2 -C 6 -alkynyl, C 3 -C 7 -cycloalkyl, hydroxy-d-C 6 -alkylene, hydroxy-C 3 - C 6 -alkenylene, hydroxy-C 3 -C 6 -alkynylene, d-C 6 -alkyloxy, C 1 -C 6 - alkyloxy-d-C 6 -alkylene, C 3 -C 7 -cycloalkyloxy, C 3 -C 7 -cycloalkyl-C 1 -C 6 - alkylenoxy, C 3 -C 7 -cycloalkyloxy-Ci-C 6 -alkylene, d-C 6 -alkyloxy-C 3 -C 6 - alkenylene, Ci-C 6 -alkyl
  • R3, R4, R5 may be independently of one another hydrogen, hydroxy, halogen, nitro, amino, cyano, phenyl, d-C 6 -alkyl, C 2 -C 6 -alkenyl or C 2 -C 6 -alkynyl, C 3 - C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-Ci-C 6 -alkylene, C 3 -C 7 -heterocycloalkyl, where the hydrocarbon chains therein may optionally be substituted one or more times by fluorine, cyano or the radicals: or independently of one another hydroxy-Ci-C 6 -alkylene, hydroxy-C 3 -C 6 - alkenylene, hydroxy-C 3 -C 6 -alkynylene, Ci-C 6 -alkyloxy, C 3 -C 7 - cycloalkyloxy, C 3 -C 7 -cycloalkyl-Ci
  • R3 and R4 may together form heterocycloalkyl, cycloalkyl
  • Q is an aryl or heteroaryl group or the group
  • A is a monocyclic aryl or a monocyclic heteroaryl group
  • V is a cycloalkylen, cycloalkenylen, heterocycloalkylen or heterocycloalkenylen group
  • X is a bond or an ethinylen group
  • W is an aryl or heteroaryl group
  • R1 substitutes one or more positions of the aryl or heteroaryl ring in the indole residue
  • R2 substitutes one or more positions of the aryl or heteroaryl ring in the radical Q and or the radical V.
  • the present invention relates to both possible enantiomeric forms at the stereocentre of the tryptamine residue.
  • the unbranched C-i-C ⁇ -alkyl groups for the radicals R1 to R5 may be for example a methyl, ethyl, propyl, butyl, pentyl or a hexyl group; and the branched C 3 -C 6 -alkyl groups for the radicals R1 to R6 may be an /sopropyl, /sobutyl, sec-butyl, terf-butyl,
  • the branched or unbranched C 2 -C 6 -alkenyl groups for the radical R2 to R5 may be for example a vinyl, allyl, (E)-2-methylvinyl, (Z)-2-methylvinyl, homoallyl, (£)-but-2-enyl, (Z)- but-2-enyl, (£)-but-1-enyl, (Z)-but-i-enyl, pent-4-enyl, (£)-pent-3-enyl, (Z)-pent-3-enyl, (£)-pent-2-enyl, (Z)-pent-2-enyl, (£)-pent-1-enyl, (Z)-pent-i-enyl, hex-5-enyl, (£)-hex-4- enyl, (Z)-hex-4-enyl, (£)-hex-3-enyl, (Z)-hex-3-enyl, (£)-he
  • the Cs-C ⁇ -alkynyl groups for the radicals R2 to R5 may be for example an ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, 1- methylprop-2-ynyl, 2-methylbut-3-ynyl, 1-methylbut-3-ynyl, 1-methylbut-2-ynyl, 3- methylbut-1-ynyl, 1-ethylprop-2-ynyl, 3-methylpent-4-ynyl, 2-methylpent-4-ynyl, 1- methylpent-4
  • the Ci-C 6 -alkyloxy groups for the radicals R2 to R5 may be for example a methyloxy, ethyloxy, propyloxy, /sopropyloxy, butyloxy, /sobutyloxy, sec-butyloxy, te/t-butyloxy, pentyloxy, /sopentyloxy, (2-methyl butyl )oxy, (i-methylbutyl)oxy, (i-ethylpropyl)oxy, neopentyloxy, (1 ,1-dimethylpropyl)oxy, hexyloxy, (4-methylpentyl)oxy, (3-methylpentyl)- oxy, (2-methyl pentyl)oxy, (i-methylpentyl)oxy, (i-ethylbutyl)oxy, (2-ethylbutyl)oxy, (3,3- dimethylbutyl)oxy, (2,2-dimethylbutyl)oxy,
  • halogens for the radicals R1 to R5 are fluorine, chlorine, bromine or iodine.
  • Ci-C 3 -alkylsulphanyl groups for the radicals R3 to R5 may be for example a methylsulphanyl (CH 3 S-), ethylsulphanyl (CH 3 CH 2 S-), propylsulphanyl, /sopropyl- sulphanyl group.
  • the d-Ce-alkylaminocarbonyl groups for the radicals R3 to R5 may be for example a methylaminocarbonyl-, ethylaminocarbonyl-, propylaminocarbonyl-, /sopropylamino- carbonyl-, butylaminocarbonyl-, /sobutylaminocarbonyl-, sec-butylaminocarbonyl-, tert- butylaminocarbonyl-, pentylaminocarbonyl-, /sopentylaminocarbonyl-, (2-methylbutyl)- aminocarbonyl-, (i-methylbutyl)aminocarbonyl-, (i-ethylpropyl)aminocarbonyl-, neo- penfylaminocarbonyl-, (1 ,1-dimethylpropyl)aminocarbonyl-, hexylaminocarbonyl-, (4- methyl
  • the hydroxy-Ci-C ⁇ -alkylene groups for the radicals R3 to R5 may be a hydroxymethyl (HOCH 2 -), 2-hydroxyethyl (HOCH 2 CH 2 -), 1-hydroxyethyl [CH 3 CH(OH)-], 3-hydroxy- propyl (HOCH 2 CH 2 CH 2 -), 2-hydroxypropyl [CH 3 CH(OH)CH 2 -], 1-hydroxypropyl [CH 3 CH 2 CH(OH)-], 2-hydroxy-1-methylethyl [HOCH 2 CH(CH 3 )-], 1-hydroxy-1-methyl- ethyl [(CHa) 2 C(OH)-], 4-hydroxybutyl (HOCH 2 CH 2 CH 2 CH 2 -), 3-hydroxybutyl [CH 3 CH(OH)CH 2 CH 2 -], 2-hydroxybutyl [CH 3 CH 2 CH(OH)CH 2 -], 1-hydroxybutyl [CH 3 CH 2 CH(OH)-], 3-hydroxy-1-methylpropyl [HOCH 2 CH 2 CH(CH 3 )
  • heterocycloalkyl groups which may form the radicals R3 and R4 together may be for example the following groups:
  • cycloalkyl groups which may form the radicals R3 and R4 together may be for example the following groups:
  • the C 3 -C 7 -cycl oa Iky I groups for the radicals R2 to R5 may be for example a cyclopro- pyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl group.
  • the C 3 -C 7 -heterocycloalkyl groups for the radicals R1 to R5 may be for example a cyclopropyl, cyclobutyl, cycopentyl, cyclohexyl, cycloheptyl group in which one or two carbon atoms of the ring are replaced independently of one another by an oxygen, nitrogen or sulphur atom.
  • the monocyclic aryl group for A may be for example a phenyl group which is linked via substitutable positions.
  • the aryl group for W or Q may be for example a phenyl, naphthyl group which is linked via substitutable positions.
  • the monocylic heteroaryl group for A may be for example a pyridinyl, pyrimidinyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, pyrrolyl, pyrazolyl or an imidazolyl group which is linked via substitutable positions.
  • the heteroaryl group for W or Q may be for example a pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, 1.5-naphthyridinyl, 1 ,6- naphthyridinyl, 1 ,7-naphthyridinyl, 1 ,8-naphthyridinyl, benzofuranyl, benzothienyl, 1 ,3- benzodioxolyl, 2,1 ,3-benzothiadiazolyl, indolyl, indazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, pyrrolyl, pyrazolyl or an imidazolyl group which is linked via substitutable positions.
  • heterocycloalkylen groups for V may be for example the following groups:
  • heterocycloalkenylen groups for V may be for example the following groups:
  • the cycloalkylen groups for V may be for example the following groups:
  • the cycloalkenylen groups for V may be for example the following groups:
  • the C 3 -C 7 -cycloalkyloxy groups for the radicals R2 to R5 may be for example a cyclo- propyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy group.
  • the d-Ce-alkylamino groups for the radicals R1 to R6 may be for example methyl- amino, ethylamino, propylamine /sopropylamino, butylamino, /sobutylamino, sec-butyl- amino, te/t-butylamino, pentylamino, /sopentylamino, (2-methylbutyl)amino, (1-methyl- butyl)amino, (i-ethylpropyl)amino, neopentylamino, (1 ,1-dimethylpropyl)amino, hexyl- amino, (4-methylpentyl)amino, (3-methylpentyl)amino, (2-methylpentyl)amino, (i-methylpentyl)amino, (i-ethylbutyl)amino, (2-ethylbutyl)amin
  • each of the two radicals on the nitrogen atom of the dialkylamino group may be chosen independently of one another from the following radicals: possible examples are a methyl, ethyl, propyl, /sopro- pyl, butyl, /sobutyl, sec-butyl, terf-butyl, pentyl, /sopentyl, (2-methylbutyl), (1 -methyl- butyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3- methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-di- methylbutyl), (2,2-dimethylbutyl
  • each of the C 3 -C 7 -cycloalkyl groups of the C 3 -C 7 -cycloalkyl-Ci-C 6 - alkyleneoxy group for example of a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group, independently of one another with each C0-C6-alkyleneoxy group, for example with a methyleneoxy, ethyleneoxy, propyleneoxy, butyleneoxy, pentylene- oxy, hexyleneoxy group.
  • hydroxy-C 3 -C 6 -alkenylene groups for the radicals R2 to R5 it is possible for the hydroxy group to be located on any desired position of the C 3 -C 6 -alkenyl group, for example of an allyl, (E)-2-methylvinyl, (Z)-2-methylvinyl, homoallyl, (£)-but-2-enyl, (Z)-but- 2-enyl, (E)-but-i-enyl, (Z)-but-i-enyl, pent-4-enyl, (£)-pent-3-enyl, (Z)-pent-3-enyl, (E)- Pent-2-enyl-, (Z)-Pent-2-enyl-, (E)-Pent-i-enyl-, (Z)-Pent-i-enyl-, hex-5-enyl-, (E)-hex- 4-enyl, (Z)-hex-4-enyl,
  • the hy- droxy group is located at any desired position of the C 3 -C 6 -alkynyl group, for example of a prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, pent-1-ynyl, pent-2- ynyl, pent-3-ynyl, pent-4-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, 1-methylprop-2-ynyl, 2-methylbut-3-ynyl, 1-methylbut-3-ynyl, 1-methylbut-2-ynyl, 3- methylbut-1-ynyl, 1-ethylprop-2-
  • Ci-C 6 -alkyloxy group for example a methyloxy, ethyloxy, propyloxy, /sopropyloxy, butyloxy, /sobutyloxy, sec-butyloxy, terf-butyloxy, pentyloxy, /sopentyloxy, (2-methyl- butyl)oxy, (i-methylbutyl)oxy, (i-ethylpropyl)oxy, neopentyloxy, (1 ,1-dimethylpropyl)oxy, hexyloxy, (4-methylpentyl)oxy, (3-methylpentyl)oxy, (2-methylpentyl)oxy, (1-methyl- pentyl)oxy, (i-ethylbutyl)oxy, (2-ethylbutyl)oxy, (3,3-
  • Ci-C 6 -alkyloxy-C 3 -C 6 -alkynylene groups for the radicals R2 to R5 it is possible for the Ci-C 6 -alkyloxy group, for example a methyloxy, ethyloxy, propyloxy, /sopropyloxy, butyloxy, /sobutyloxy, sec-butyloxy, terf-butyloxy, pentyloxy, /sopentyloxy, (2-methyl- butyl)oxy, (i-methylbutyl)oxy, (i-ethylpropyl)oxy, neopentyloxy, (1 ,1-dimethylpropyl)oxy, hexyloxy, (4-methylpentyl)oxy, (3-methylpentyl)oxy, (2-methylpentyl)oxy, (1-methyl- pentyl)oxy, (i-ethylbutyl)oxy, (2-ethylbutyl)oxy,
  • each of the C 3 -C 7 -cycloalkyl groups of the C 3 -C 7 -cycloalkyl-(C 0 -C 6 )-alkylene- amino group for example of a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclo- heptyl group, to be combined independently of one another with each Co-C ⁇ -alkylene group, for example with a bond, a methylene, ethylene, propylene, butylene, pentylene, hexylene group.
  • Ci-C ⁇ -alkyloxy-d-Ce-alkylene groups for the radical R2 to R5, it is possible for the Ci-C ⁇ -alkyloxy group to be selected independently for example from methyloxy, ethyloxy, propyloxy, /sopropyloxy, butyloxy, /sobutyloxy, sec-butyloxy, terf-butyloxy, pentyloxy, /sopentyloxy, (2-methyl butyl )oxy, (i-methylbutyl)oxy, (i-ethylpropyl)oxy, neopentyloxy, (1 ,1-dimethylpropyl)oxy, hexyloxy, (4-methylpentyl)oxy, (3-methylpentyl)- oxy, (2-methylpentyl)oxy, (i-methylpentyl)oxy, (i-ethylbutyl)oxy, (2-ethylbutyl)oxy, (3,3
  • each of the two radicals on the nitrogen atom of the amino group is selected independently for example from methyl, ethyl, propyl, /sopropyl, butyl, /sobutyl, sec-butyl, terf-butyl, pentyl, /sopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1- methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1- dimethyl,
  • the C 3 -C 7 -cycloalkyl-Ci-C 6 -alkylene groups for the radicals R2 to R5 may be for exam- pie a cyclopropyloxymethylene, cyclopropyloxyethylene, cyclopropyloxypropylene, cyclopropyloxybutylene, cyclopropyloxypentylene, cyclopropyloxyhexylene, cyclobuty- loxymethylene, cyclobutyloxyethylene, cyclobutyloxypropylene, cyclobutyloxybutylene, cyclobutyloxypentylene, cyclobutyloxyhexylene, cyclopentyloxymethylene, cyclopenty- loxyethylene, cyclopentyloxypropylene, cyclopentyloxybutylene, cyclopentyloxypenty- lene, cyclopentyloxyhexylene, cyclohexyloxymethylene
  • Ci-C 6 -alkylamino-Ci-C 6 -alkylene groups for the radicals R2 to R5 it is possible for the Ci-C6-alkylamino group to be selected independently for example from methyl- amino, ethylamino, propylamine /sopropylamino, butylamino, /sobutylamino, sec-butyl- amino, te/t-butylamino, pentylamino, /sopentylamino, (2-methylbutyl)amino, (1-methyl- butyl)amino, (i-ethylpropyl)amino, neopenfylamino, (1 ,1-dimethylpropyl)amino, hexyl- amino, (4-methylpentyl)amino, (3-methylpentyl)amino, (2-methylpentyl)amino, (1- methylpentyl)a
  • each of the C 1 -C 6 -BCyI groups for example a formyl, acetyl, propionyl, 2-methylpro- pionyl, 2,2-dimethylpropionyl, butyryl, 2-methylbutyryl, 3-methylbutyryl, 2,2-dimethyl- butyryl, 2-ethylbutyryl, pentanoyl, 2-methylpentanoyl, 3-methylpentanoyl, 4-methyl- pentanoyl or a hexanoyl group, to be combined independently of one another with each (C 0 -C 6 -alkyl)amido group, for example a hydrogen atom, a methylamido, ethylamido, propylamido, isopropylamido, butylamido, isobutylamido
  • the Ci-C 6 -alkylaminocarbonyl groups for the radicals R3 to R5 may be for example a methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylamino- carbonyl, butylaminocarbonyl, isobutylaminocarbonyl, sec-butylaminocarbonyl, tert-butylaminocarbonyl, pentylaminocarbonyl, isopentylaminocarbonyl, (2-methylbutyl)- aminocarbonyl, (i-methylbutyl)aminocarbonyl, (i-ethylpropyl)aminocarbonyl, neopen- tylaminocarbonyl, (1 ,1-dimethylpropyl)aminocarbonyl, hexylaminocarbonyl, (4-methyl- pentyl)aminocarbonyl, (3-methylpentyl)amin
  • each of the two CrC ⁇ -alkyl radicals on the nitrogen atom of the di(CrC 6 -alkyl)aminocarbonyl group may be independently of one another for example a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethyl- propyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2- methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-di-
  • the (C 3 -C 7 -cycloalkyl)aminocarbonyl groups for the radicals R3 to R5 may be for example a cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocar- bonyl, cyclohexylaminocarbonyl or cycloheptylaminocarbonyl group.
  • each of the two C 3 -C 7 -cycloalkyl radicals on the nitrogen atom of the di(C 3 -C 7 -cycloalkyl)amino- carbonyl group may be independently of one another for example a cyclopropyl, cyclo- butyl, cyclopentyl, cyclohexyl or cycloheptyl group.
  • each of the C 3 -C 7 -cycloalkyl groups of the C 3 -C 7 -cycloalkyl-Ci-C 6 -alkyl- eneaminocarbonyl groups for example of a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group, to be combined independently of one another with each d- C 6 -alkyleneaminocarbonyl group, for example with a methyleneaminocarbonyl, ethyl- eneaminocarbonyl, propyleneaminocarbonyl, butyleneaminocarbonyl, pentylene- aminocarbonyl, hexyleneaminocarbonyl group.
  • the Ci-C 6 -alkylcarbonyl groups for the radicals R3 to R5 may be for example a methyl- carbonyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl, isobutylcar- bonyl, sec-butylcarbonyl, tert-butylcarbonyl, pentylcarbonyl, isopentylcarbonyl, (2- methylbutyl)carbonyl, (i-methylbutyl)carbonyl, (i-ethylpropyl)carbonyl, neopentylcarbonyl, (1 ,1-dimethylpropyl)carbonyl, hexylcarbonyl, (4-methylpentyl)car- bonyl, (3-methylpentyl)carbonyl, (2-methylpentyl)carbonyl, (i-methylpentyl)carbonyl, (1- ethylbutyl)carbon
  • the C3-C7-cycloalkylcarbonyl groups for the radicals R3 to R5 may be for example a cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl or cycloheptylcarbonyl group.
  • the Ci-C 6 -alkyloxycarbonyl groups for the radicals R3 to R5 may be for example a me- thyloxycarbonyl, ethyloxycarbonyl, propyloxycarbonyl, isopropyloxycarbonyl, butyloxy- carbonyl, isobutyloxycarbonyl, sec-butyloxycarbonyl, tert-butyloxycarbonyl, pentyloxy- carbonyl, isopentyloxycarbonyl, (2-methylbutyl)oxycarbonyl, (i-methylbutyl)oxycarbonyl, (1 -ethylpropyl)oxycarbonyl, neopentyloxycarbonyl, (1 , 1 -dimethylpropyl)oxycarbonyl, hexyloxycarbonyl, (4-methylpentyl)oxycarbonyl, (3-methylpentyl)oxycarbonyl, (2-methyl- pentyl)oxycarbonyl, (i-
  • the CrCe-alkylsulphonyl groups for the radicals R3 to R5 may be for example a me- thylsulphonyl, ethylsulphonyl, propylsulphonyl, isopropylsulphonyl, butylsulphonyl, iso- butylsulphonyl, sec-butylsulphonyl, tert-butylsulphonyl, pentylsulphonyl, isopentylsul- phonyl, (2-methylbutyl)sulphonyl, (i-methylbutyl)sulphonyl, (i-ethylpropyl)sulphonyl, neopentylsulphonyl, (1 ,1-dimethylpropyl)sulphonyl, hexylsulphonyl, (4-methylpentyl)- sulphonyl, (3-methylpentyl)sulphony
  • the C 3 -C 7 -cycloalkylsulphonyl groups for the radicals R3 to R5 may be for example a cyclopropylsulphonyl, cyclobutylsulphonyl, cyclopentylsulphonyl, cyclohexylsulphonyl or cycloheptylsulphonyl group.
  • each of the C 3 -C 7 -cycloalkyl groups of the C 3 -C 7 -cycloalkyl-Ci-C 6 -alkylene- sulphonyl groups for example of a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group, to be combined independently of one another with each d-C 6 -alkyl- enesulphonyl group, for example with a methylenesulphonyl, ethylenesulphonyl, propyl- enesulphonyl, butylenesulphonyl, pentylenesulphonyl, hexylenesulphonyl group.
  • the C-rC 6 -alkylaminosulphonyl groups for the radicals R3 to R5 may be for example a methylaminosulphonyl, ethylaminosulphonyl, propylaminosulphonyl, isopropylaminosul- phonyl, butylaminosulphonyl, isobutylaminosulphonyl, sec-butylaminosulphonyl, tert- butylaminosulphonyl, pentylaminosulphonyl, isopentylaminosulphonyl, (2-methylbutyl)- aminosulphonyl, (i-methylbutyl)aminosulphonyl, (i-ethylpropyl)aminosulphonyl, neopentylaminosulphonyl, (1 , 1 -dimethylpropyl)aminosulphonyl, hexylaminosulphonyl, (4-methylpentyl)aminosul
  • each of the two Ci-C 6 -alkyl radicals on the nitrogen atom of the di(CrC 6 -alkyl)aminosulphonyl group may be independently of one another for example a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1- ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-di
  • the (C 3 -C 7 -cycloalkyl)aminosulphonyl groups for the radicals R3 to R5 may be for example a cyclopropylaminosulphonyl, cyclobutylaminosulphonyl, cyclopentylaminosul- phonyl, cyclohexylaminosulphonyl or cycloheptylaminosulphonyl group.
  • each of the two C 3 -C 7 -cycloalkyl radicals on the nitrogen atom of the di(C 3 -C 7 -cycloalkyl)amino- sulphonyl group may be independently of one another for example a cyclopropyl, cyclo- butyl, cyclopentyl, cyclohexyl or cycloheptyl group.
  • each of the C 3 -C 7 -cycloalkyl groups of the C 3 -C 7 -cycloalkyl-Ci-C 6 -alkyleneaminosul- phonyl groups can be combined independently of one another with each CrC 6 - alkyleneaminosulphonyl group, for example with a methyleneaminosulphonyl, ethyl- eneaminosulphonyl, propyleneaminosulphonyl, butyleneaminosulphonyl, pentyleneami- nosulphonyl, hexyleneaminosulphonyl group.
  • the C-rC 6 -alkylsulphonylamido groups for the radicals R3 to R5 may be for example a methylsulphonylamido, ethylsulphonylamido, propylsulphonylamido, isopropylsulphon- ylamido, butylsulphonylamido, isobutylsulphonylamido, sec-butylsulphonylamido, tert- butylsulphonylamido, pentylsulphonylamido, isopentylsulphonylamido, (2-methylbutyl)- sulphonylamido, (i-methylbutyl)sulphonylamido, (i-ethylpropyl)sulphonylamido, neo- pentylsulphonylamido, (1 ,1-dimethylpropyl)sulphonylamido, hexyl
  • each of the (C 0 -C 6 -alkyl) groups on the nitrogen atom of the -N(C 0 -C 6 -alkyl)-C(O)-Ci-C 6 -alkyl groups for example a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methyl- pentyl), (1-methylpentyl), (1-ethyl), (1-ethy
  • each of the (C 0 -C 6 -alkyl) groups on the nitrogen atom of the -N(C 0 -C 6 -alkyl)-C(O)-Ci-C 6 -alkyl groups for example a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbut
  • all three (C 0 -C 6 -alkyl) groups may be independently of one another a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3- dimethylbutyl), (2,2-dimethylbut
  • both (C 0 -C 6 -alkyl) groups may be independently of one another a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3- dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbut
  • each of the (Co-Ce-alkyl) groups on the nitrogen atom of the -N(C 0 -C6-alkyl)-C(O)-NH-(C 3 -C 7 - cycloalkyl) groups for example a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2- methylpentyl), (1-methylpentyl), (1-methylmethylpentyl), (1-methylmethylpentyl), (1-methylmethylpentyl), (1-methylmethylpentyl), (1-methylmethylpentyl), (1-
  • each of the (C 0 -C 6 -alkyl) groups on the nitrogen atom of the -N(Co-C 6 -alkyl)-S ⁇ 2 -(Ci-C 6 -alkyl) group for example a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbuty
  • each of the (Co-C ⁇ -alkyl) groups on the nitrogen atom of the -N(C 0 -C 6 -alkyl)-S ⁇ 2 -C 3 -C 7 -cycloalkyl group for example a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methyl- pentyl), (1-methylpentyl), (1-ethyl), (1-ethyl), (1-ethyl), (1-ethyl), (1-ethyl), (1-ethyl), (1-ethyl), (1-
  • all three (C 0 -C 6 -alkyl) groups may be independently of one another a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3- dimethylbutyl), (2,2-dimethylbutyl), (1
  • the C 0 -C 6 -alkyl group of the -N(Co-C 6 -alkyl)-S ⁇ 2 -NH-(C 3 -C 7 )-cycloalkyl group for example a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pen- tyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-methylpentyl), (1-methylpentyl), (1-methylpentyl), (1-methylpentyl), (1-methylpentyl), (1-methylpentyl), (1-methylpenty
  • each of the C 2 -C 6 -alkylene groups on the nitrogen atom of the -C(O)-N(H)-C 2 -C 6 -alkyl- ene-(Ci-C 6 -alkyl)amine group for example an ethylene, propylene, butylene, pentylene or hexylene group
  • each CrC 6 - alkyl group on the amino group for example with a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1- ethylpropyl), neopentyl,
  • each of the C 2 -C 6 -alkylene groups on the nitrogen atom of the -C(O)-N(H)-C 2 -C 6 - alkylene-[di(CrC 6 -alkyl)]amine group for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each of the two identically or different Ci-C 6 -alkyl groups on the amino group, for example with a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl
  • each of the (C 2 -C 6 -alkylene) groups of the -C(O)-N(H)-C 2 -C 6 -alkylene-(C 3 -C 7 -cyclo- alkyl)amine group for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each C 3 -C 7 -cycloalkyl group on the amine, for example with a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group.
  • each of the (C 2 -C 6 -alkylene) groups of the -C(O)-N(H)-C 2 -C 6 - alkylene-(C 3 -C 6 -cycloalkyl-Ci-C 6 -alkylene)amine group for example an ethylene, pro- pylene, butylene, pentylene or hexylene group, may be combined independently of one another with each C 3 -C 7 -cycloalkyl-Ci-C 6 -alkylene group on the amine, for example with a cyclopropylmethylene, cyclopropylethylene, cyclopropylpropylene, cyclopropylbuty- lene, cyclopropylp
  • the (C 2 -C 6 -alkylene) groups of the -S(O 2 )-N(H)-C 2 -C 6 -alkylene-(C 1 -C 6 -alkyl)amine group for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each d-Ce-alkyl group on the amino group, for example with a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert- butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,
  • the C 2 -C 6 -alkylene group of the -S(O 2 )-N(H)-C 2 -C6-alkylene-[di(Ci-C 6 -alkyl)]amine group for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each of the two Ci-C 6 -alkyl groups on the amino group, for example with a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl,
  • the C 2 -C 6 -alkylene group of the -S(O 2 )-N(H)-C 2 -C 6 -alkylene-(C 3 -C 7 -cycloalkyl)- amine group for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each C 3 -C 7 -cycloalkyl group on the amino group, for example with a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group.
  • each C 2 -C 6 -alkylene group of the -S(O 2 )-N(H)-C 2 -C 6 -alkylene- (C 3 -C 7 -cycloalkyl-Ci-C 6 -alkylene)amine group for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each C 3 -C 7 -cycloalkyl-Ci-C 6 -alkylene group on the amine, for example with a cyclo- propylmethylene, cyclopropylethylene, cyclopropylpropylene, cyclopropylbutylene, cyclopropylpentylene,
  • the C 2 -C 6 - alkylene group of the -O-C 2 -C 6 -alkylene-(Ci-C 6 -alkyl)amine group for example an ethylene, propylene, butylene, pentylene or hexylene group
  • each d-C 6 -alkyl group on the amino group for example a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2- methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4- methylpenty
  • the C 2 - C 6 -alkylene group of the -O-C 2 -C 6 -alkylene-[di(Ci-C 6 -alkyl)]amine group for example an ethylene, propylene, butylene, pentylene or hexylene group
  • the C 2 - C 6 -alkylene group of the -O-C 2 -C 6 -alkylene-[di(Ci-C 6 -alkyl)]amine group for example an ethylene, propylene, butylene, pentylene or hexylene group
  • may be combined independently of one another with two freely selectable CrC ⁇ -alkyl groups on the amino group for example with a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert- butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethy
  • the method is based on a competitive immunoassay between native cAMP, which has been produced by the cells, and cAMP which is labelled with cAMPD2 conjugate.
  • the specific signal is inversely proportional to the cAMP concentration of the samples employed.
  • the 665nm/ 620nm fluorescence ratio was evaluated.
  • 96-well plates for the tissue culture 96-well plates with black edge and black base (e.g. Fluotrac 600 from Greiner), 96-well plates for the substance dilutions of polypropylene and cAMP Femtomolar (4000wells Kit, CIS Bio International # 62AM5PEJ).
  • BSA bovine serum albumin
  • IBMX 3-isobutyl-1-methylxanthine
  • hFSH human follicle stimulating hormone
  • Triton X-100 analytical grade potassium fluoride analytical grade
  • G 418 Geneeticin
  • Accutase The following reagents were used: BSA (bovine serum albumin) Fraction V protease-free, IBMX (3-isobutyl-1-methylxanthine), hFSH (human follicle stimulating hormone), Triton X-100 analytical grade, potassium fluoride analytical grade, G 418 (Geneticin) and Accutase.
  • Buffer 1 (washing and testing buffer) contained PBS, 1 mM CaCI2, 1 mM MgCI 2 , 0.2% glucose; 0.1% BSA, 1 mM IBMX.
  • Buffer 2 (2x lysis buffer) contained 1 % Triton X-100 in PBS (without CaCI 2 and MgCI 2 ).
  • Buffer 3 (assay buffer) contained 50 mM potassium phosphate buffer (pH 7.0); 800 mM potassium fluoride; 0.2% BSA (always added fresh).
  • the cells were seeded in 96-well plates (3x10 4 cells per well hFSHR clone 16 cells (CHO cells stably transfected with the human FSH receptor in 150 ⁇ l of medium). The next day, test substance dilutions were made up. For this purpose, all the substances were diluted in ice-cold buffer 1 (with or without hFSH), and the substance dilutions were placed on ice until applied to the cells.
  • the cell supernatant was then aspirated off, and the cells were washed 2x with 200 ⁇ l of buffer 1.
  • the cells were treated with 60 ⁇ l of the appropriate substance concentrations at 37 0 C for 2h.
  • the cells were then lysed with 60 ⁇ l of buffer 2 (put onto the supernatant) (on a plate shaker at RT for 30 min).
  • test conjugates (cAMP-D2 and anti-cAMP cryptate, CIS Bio) were diluted in buffer 3 in accordance with the manufacturers' information.
  • the actual mixture for measurement was pipetted into a black 96-well plate (in each case 15 ⁇ l of the cell lysate diluted with 35 ⁇ l of buffer 1 ; firstly 25 ⁇ l of cAMP-D2 conjugate were pipetted and, after 10 min, 25 ⁇ l of the anti-cAMP cryptate were added). This is followed by incubation at RT for 90 minutes.
  • the measurement was carried out in a PheraStar (BMG).
  • Dose-effect curve (hFSH) for the human receptor 1 e-8, 3e-9, 1 e-9, 3e-10, 1 e-10, 3e-
  • test substances were employed in suitable dilutions in the absence (test for agonism) and in the presence of 1 e-9 mol/l hFSH.
  • compounds of the general formula I and their pharmaceutically acceptable salts can thus be used for the fertility control in male and/or in a female animals, in particular in men and/or women; as well as for the treatment and/or prevention of osteoporosis.
  • the invention further relates to compounds of the general formula I or pharmaceutically acceptable salts thereof as therapeutic active ingredients, and to pharmaceutical compositions comprising at least one compound of the general formula I or pharmaceutically acceptable salts thereof, where appropriate together with pharmaceutically suitable excipients and/or carriers.
  • salts of the compounds of the general formula I can be prepared by methods known to the skilled person, depending on the nature of the compound of formula I, either by using as inorganic acids inter alia hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid, nitric acid, as carboxylic acids inter alia acetic acid, propionic acid, hexanoic acid, octanoic acid, decanoic acid, oleic acid, stearic acid, maleic acid, fumaric acid, succinic acid, benzoic acid, ascorbic acid, oxalic acid, salicylic acid, tartaric acid, citric acid, lactic acid, glycolic acid, malic acid, mandelic acid, cinnamic acid, glutamic acid, aspartic acid, and as sulphonic acids inter alia methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid and
  • compositions and medicaments may be intended for oral, rectal, subcutaneous, transdermal, percutaneous, intravenous or intramuscular administration. They comprise besides conventional carriers and/or diluents at least one compound of the general formula I.
  • the medicaments of the invention are formulated using the customary solid or liquid carriers or diluents and the excipients customarily used in pharmaceutical technology, in accordance with the desired mode of administration with a suitable dosage in a known manner: i.e. by processing the active ingredient with the carrier substances, fillers, substances which influence disintegration, binders, humectants, lubricants, absorbents, diluents, test modifiers, colorants etc.
  • compositions according to the present invention are preferably administered orally. Suitable for oral administration are in particular tablets, (film)- coated tablets, sugar-coated tablets capsules, pills, powders, granules, pastilles, suspensions, emulsions, solutions or depot forms.
  • Appropriate tablets can be obtained for example by mixing the active ingredient with known excipients, for example inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, disintegrants such as maize starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/ or agents to achieve a depot effect such as carboxylpolymethylene, carboxylmethylcellulose, cellulose acetate phthalate or polyvinyl acetate.
  • the tablets may also consist of a plurality of layers.
  • coated tablets can be produced by coating cores which have been produced in analogy to the tablets with agents normally used in tablet coatings, for example polyvinylpyrrolidone or shellac, gum Arabic, talc, titanium oxide or sugar.
  • the tablet coating may also consist of a plurality of layers, it being possible to use the excipients mentioned above for tablets.
  • Solutions or suspensions with the compounds according to the invention of the general formula I may additionally comprise taste-improving agents such as saccharin, cyclamate or sugar and, for example, flavourings such as vanillin or orange extract. They may additionally comprise suspending aids such as sodium carboxymethylcellulose or preservatives such as p-hydroxybenzoates.
  • Capsules comprising the compounds of the general formula I can be produced for example by the compound(s) of the general formula I being mixed with an inert carrier such as lactose or sorbitol and encapsulated in gelatine capsules.
  • Parenteral preparations such as solutions for injection are also suitable. Preparations for injection and infusion are possible for parenteral administration. Appropriately prepared crystal suspensions can be used for intraarticular injection. Aqueous and oily solutions for injection or suspensions and corresponding depot preparations can be used for intramuscular injection.
  • the novel compounds can be used for rectal administration in the form of suppositories, capsules, solutions (e.g. in the form of enemas) and ointments both for systemic and for local therapy.
  • Suitable suppositories can be produced for example by mixing with carriers intended for this purpose, such as neutral fats or polyethylene glycol or derivatives thereof.
  • Formulations suitable for topical application include gels, ointments, greasy ointments, creams, pastes, dusting powders, milk and tinctures. Topical use can also take place by means of a transdermal system, for example a patch.
  • concentration of the compounds of the general formula I in these preparations should typically be in the range of 0.01 % - 20% in order to achieve an adequate pharmacological effect.
  • the invention further relates to pharmaceutical compositions in combination with packaging material suitable for said composition, wherein said packaging material including instructions for the use of the composition.
  • Suitable doses for the compounds according to the present invention may vary from 0.005 mg to 50 mg per day per kg of body weight, depending on the age and constitution of the patient. It is possible to administer the necessary daily dose by single or multiple delivery.
  • the preferred daily dose for larger mammals, for example humans may vary in the range from 10 ⁇ g to 30 mg per kg of body weight.
  • the exact dose and regimen of administration of the drug substance (active ingredient, or a pharmaceutical composition thereof, may however vary with the particular compound, the route of administration, and the age, sex and condition of the individual to whom the medicament is administered.
  • the dose, the dosage as well as the regimen of the administration may thus differ between a male and a female considerably.
  • the present invention also relates to a process for preparing the compounds according to the invention.
  • Compounds of the general formula I can be prepared as shown in Scheme 1 by an amide formation reaction between the amine Vl and the carboxylic acid VII.
  • Reagents suitable for this purpose are all suitable peptide-coupling reagents which are known to the skilled person and which convert the carboxylic acid, where appropriate in the presence of a base, into an intermediate active ester, for example PyBOP ([(1 H-benzotriazol-1 -yl)oxy]tris(pyrrolidin-1 -yl)phosphonium hexafluorophos- phate), HATU (2-(7-aza-1 H-benzotriazol-1 -yl)-1 ,1 , 3, 3-tetramethyluronium hexafluoro- phosphate), HBTU (2-(1 H-benzotriazol-1 -yl)-1 , 1 ,3, 3-tetramethyluronium
  • Reagents suitable for this purpose are all suitable peptide-coupling reagents which are known to the skilled person and which convert the carboxylic acid, where appropriate in the presence of a base, into an intermediate active ester, for example PyBOP ([(1H-benzo- triazol-1-yl)oxy]tris(pyrrolidin-1-yl)phosphonium hexafluorophosphate), HATU (2-(7-aza- 1H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate), HBTU (2-(1 H- benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate), EDC ( ⁇ /-[3-(di- methylamino)propy
  • Compounds of the general formula V can be prepared as shown in Scheme 5 by an amide formation reaction between the amine Vl and the carboxylic acid Xl.
  • Reagents suitable for this purpose are all suitable peptide-coupling reagents which are known to the skilled person and which convert the carboxylic acid, where appropriate in the presence of a base, into an intermediate active ester, for example PyBOP ([(1H-benzotri- azol-1-yl)oxy]tris(pyrrolidin-1-yl)phosphonium hexafluorophosphate), HATU (2-(7-aza- 1H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate), HBTU (2-(1 H- benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate), EDC ( ⁇ /-[3-(di- methyla
  • Preferred metal catalysts used are typically those containing palladium or nickel, depending on the nature of the cross- coupling reaction.
  • Reagents a) EDCI, HOBt, triethylamine, DMF.
  • Reagents a) Pd(PPh 3 ) 2 CI 2 , TBAF, neat or THF; b) Pd(PPh 3 ) 2 CI 2 , CuI, Et 2 NH; c) KOH, MeOH.
  • acetylene derivatives of formula XXVII can in principle be prepared according to Scheme 14 via a Sonogashira type coupling of aryl halide XXIV and trimethylsilyl protected acetylene with subsequent hydrolysis of the trimethylsilyl protecting group.
  • acetylene derivatives of formula XXIII can in principle be prepared according to Scheme 15 via a Sonogashira type coupling of aryl halide XXVI and trimethylsilyl protected acetylene with subsequent hydrolysis of the trimethylsilyl protecting group.
  • Reagents a) Pd(PPh 3 ) 2 CI 2 , TBAF, neat or THF; b) Pd(PPh 3 ) 2 CI 2 , CuI, Et 2 NH; c) TBAF
  • the carboxylic acid derivatives of formula XXXII can in principle be prepared according to Scheme 16 via a Suzuki type coupling of boronic acid XXX or XXXIII with their corresponding aryl halides XXIV or XXVI with subsequent hydrolysis of the resulting carboxylic esters XXXI.
  • Reagents a) Pd(PPh 3 ) 2 CI 2 , TBAF, neat or THF; b) Pd(PPh 3 ) 2 CI 2 , CuI, Et 2 NH.
  • Reagents a) Pd(PPh 3 ) 4 , Na 2 CO 3 , H 2 O, EtOH, toluene.
  • Compounds of the general formula XXXIV can in principle be prepared as shown in Scheme 19 by an amide formation reaction between an amine Vl and a carboxylic acid XXXVII.
  • the reagents typically used for the coupling are EDCI and HOBt.
  • Reagents a) Pd(PPh 3 ) 4 , Na 2 CO 3 , H 2 O, EtOH, toluene.
  • Liquid ammonia (ca. 350 ml) was condensed onto a solution of -[2-Cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-4-methyl-benzenesulfonamide (15.5 g) in anhydrous THF (115 ml) at - 78 0 C.
  • Sodium metal (ca. 4 g) was added in small portions until a deep turquoise colour persists, and the reaction mix was stirred for 30 min. at -78 0 C.
  • the reaction mixture was then quenched by addition of MeOH (72 ml) and then ammonium chloride (7.2 g) and the ammonia was allowed to evaporate in the fume cupboard. The residual solvents were removed in vacuo.
  • HPLC chromatography HPLC purification: Machine: Analytical 4 channel MUX system with CTC Pal injector, Waters 1525 Pumps, Waters 2488 UV detector and Waters ZQ 2000 single quad MS detector. Column Purospher Star RP C18 4.6x125 5 ⁇ m; detection wavelength 214 nm; flow rate 2 ml/min; eluents A): 0.1 % TFA in H 2 O, B): 0.1 % TFA in ACN; gradients based on B: 1% to 99% (5') to 99% (1 ') to 1% (0.25') to 1 % (1.75'). Molecular peak (ESI, M+1 ): 550, retention time: 4.07 min. The following compounds were obtained in analogy to the preparation methods described in detail:
  • the present invention further relates to the aryl halides of the formulae XIII, XIV or XVI as intermediates of the process according to the invention for preparing the compounds according to the invention, namely:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to cyanomethyl substituted N-acyl tryptamines of the formula (I) in which R1, R2, R3, R4, R5, Q, X and W have the meaning as defined in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis.

Description

Cyanomethyl substituted N-Acyl Tryptamines
The present invention relates to novel cyanomethyl substituted N-acyl tryptamines with FSH-receptor antagonist activity. The present invention also relates to a process for their preparation, pharmaceutical compositions comprising the compounds according to the invention, and the use thereof for fertility control in men or women, for the treatment and/or prevention of osteoporosis. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are together responsible for the control of male and female fertility and of the production of sex steroids.
In the female mammal, FSH controls the early ripening of ovarian primary follicles and the biosynthesis of sex steroids. In the advanced stage of differentiation (preantral follicles), the influence of LH becomes increasingly important for further development of the follicles until ovulation occurs.
In male mammals, FSH is primarily responsible for the differentiation and stimulation of Sertoli cells. Their function consists of assisting spermatogenesis on many levels. LH is primarily responsible for stimulating the Leydig cells and thus androgen production. FSH, LH and TSH (thyrotropic hormone) together form the group of glycoprotein hormones which are formed in the pituitary and are secreted from there. Whereas the alpha subunit is common to the three hormones, their specificity of action is determined by the beta chain which is unique in each case. The molecular weight of FSH including the sugar portion is about 30 kD. FSH and the other glycoprotein hormones act specifically via their selectively expressed G protein-coupled receptor (GPCR). FSH stimulates, through binding to its receptor, the association thereof with a stimulating G protein (Gs) which is thereby stimulated to hydrolyse guanosine triphosphate (GTP) and to activate the membrane-associated adenylate cyclase. Cyclic adenosine monophosphate (cAMP) is accordingly an important and readily quantifiable secondary messenger substance of FSH (G. Vassart, L. Pardo, S. Costagliola, Trends Biochem. Sci. 2004, 29, 119-126).
The importance of FSH for male fertility is the subject of intensive research. It has been possible to show that FSH influences several processes of spermatogenesis such as the proliferation of spermatogonia, the antiapoptotic effect on spermatogonia and spermatocytes and the stimulation of sperm maturation including motility thereof. The following arguments are also in favour of the FSH receptor as target for male fertility control:
1. The FSH receptor is exclusively expressed on Sertoli cells (high specificity). 2. Contraceptive vaccination against FSH beta chain or the FSH receptor induces infertility in male primates (N. R. Mougdal, M. Jeyakumar, H. N. Krishnamurthy, S.
Sridhar, H. Krishnamurthy, F. Martin, Human Reproduction Update 1997, 3, 335-
346).
3. Naturally occurring mutations in the FSH receptor or the FSH beta chain may lead to sub- or infertility in men (I. Huhtaniemi, Journal of Reproduction and Fertility
2000, 1 19, 173-186; L. C. Layman, P. G. McDonough, Molecular and Cellular Endocrinology 2000, 161 , 9-17).
4. Neutralizing FSH antiserum has no effect on testis weight and testosterone production (V. Sriraman, A. J. Rao, Molecular and Cellular Endocrionology 2004, 224, 73-82). Adverse effects of FSH blockade on androgen production therefore appear unlikely.
In line with these arguments, FSH antagonists are expected to be suitable for spermatogenesis inhibition (prevention) in men. Moreover, a suitable FSH antagonist may just as well lead to infertility in women, because it suppresses follicle ripening and thus also ovulation. On the other hand, the skilled person expects advantages from non- peptidergic FSH agonists when used to promote fertility in women (stimulation of follicle ripening). There are no reports of experience on the use of FSH or FSH agonists in male infertility, but specific indications are also conceivable in this connection. New findings demonstrate that there is also a direct effect of FSH on cells of bone metabolism. There are two fundamentally different cell types in bones: osteoclasts and osteoblasts. While osteoclasts play a central role in bone resorption (breakdown of bone), osteoblasts simulate bone density (anabolic effect). FSH receptors have been detected in osteoclasts but not in osteoblasts. In vitro, FSH stimulates bone resorption by mouse osteoclasts ( Li Sun et al. Cell 2006; 125: 247-60). A clinical correlation between the serum FSH level and low bone density has been observed in postmenopausal women (Devleta et al, J. Bone Miner. Metab. 2004, 22: 360- 4). These findings among others suggest that FSH stimulates loss of bone mass, and consequently FSH antagonists will display an antiresorptive effect on bone and are therefore suitable for the therapy and/or prevention of peri- and postmenopausal loss of bone mass and osteoporosis.
FSH receptor modulators are compounds that have a mixed profile of both FSH receptor antagonistic and FSH receptor agonistic properties. FSH receptor modulators of various compound classes of low molecular weight, have been reported on recently. FSH receptor modulators are disclosed in WO 2004/056779, WO 2004/056780; J. Med. Chem. 2005, 48, 1697 [tetrahydroquinolines]; WO 02/70493, Bioorg. Med. Chem. Lett. 2004, 14, 1713 and 1717 [diketopiperazines]; and WO 01/47875 [sulphonamides]. FSH receptor agonists are disclosed in WO 02/09706; J. Comb. Chem. 2004, 6, 196 [Thiazolidinones]; WO 2003/020726 and WO 03/20727, Chem. Biochem. 2002, 10, 1023 {thieno[2,3-d] pyrimidines)}; WO 01/87287 [pyrazoles]; WO 00/08015 [carbazoles]; WO 06/1 17023, WO 06/117368, WO 06/117370, WO 06/1 17371 , [hexahydroquino- lines].
FSH receptor antagonists are disclosed in WO 03/004028 [tetrahydroquinolines], WO 02/09705 [thiazolidinones], WO 00/58277, Bioorg. Med. Chem. 2002, 10, 639 [sulphonic acids]; WO 00/58276, Endocr. 2002, 143, 3822; Synth. Comm. 2002, 32, 2695 [azo compounds]; US 2006/0199806, US 2006/0258644, US 2006/0258645, US 2006/0287522 [pyrrolobenzodiazepines], WO 2007/017289 [acyltryptophanols], EP06090223.6 [1 ,2-diarylacetylene derivatives of acyltryptophanols], EP06077263.9 [bicyclic acyltryptophanols], EP07090034.5 [sulfonyltryptophanols] and EP07090059.2 [tetrahydrocarbazoles].
WO 2007/017289 is considered to be the closest prior art.
In view of the prior art, the objective technical problem to be solved according to the present invention may therefore be seen in providing alternative compounds having a FSH receptor antagonistic activity. The technical problem has been solved according to the present invention by the provision of novel compounds of the formula I
Figure imgf000005_0001
in which R1 is hydrogen, fluorine or d-C6-alkyl; where the hydrocarbon chains therein may optionally be substituted one or more times by fluorine;
R2 is hydrogen, halogen, nitro, amino, cyano, d-C6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl, C3-C7-cycloalkyl, hydroxy-d-C6-alkylene, hydroxy-C3- C6-alkenylene, hydroxy-C3-C6-alkynylene, d-C6-alkyloxy, C1-C6- alkyloxy-d-C6-alkylene, C3-C7-cycloalkyloxy, C3-C7-cycloalkyl-C1-C6- alkylenoxy, C3-C7-cycloalkyloxy-Ci-C6-alkylene, d-C6-alkyloxy-C3-C6- alkenylene, Ci-C6-alkyloxy-C3-C6-alkynylene, Ci-C6-alkylamino-Ci-C6- alkylene, di(Ci-C6-alkyl)amino-Ci-C6-alkylene; where the hydrocarbon chains therein may optionally be substituted one or more times by fluorine, cyano or hydroxy;
R3, R4, R5 may be independently of one another hydrogen, hydroxy, halogen, nitro, amino, cyano, phenyl, d-C6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl, C3- C7-cycloalkyl, C3-C7-cycloalkyl-Ci-C6-alkylene, C3-C7-heterocycloalkyl, where the hydrocarbon chains therein may optionally be substituted one or more times by fluorine, cyano or the radicals:
Figure imgf000006_0001
or independently of one another hydroxy-Ci-C6-alkylene, hydroxy-C3-C6- alkenylene, hydroxy-C3-C6-alkynylene, Ci-C6-alkyloxy, C3-C7- cycloalkyloxy, C3-C7-cycloalkyl-Ci-C6-alkylenoxy, Ci-C6-alkyloxy-Ci-C6- alkylene, C3-C7-cycloalkyloxy-Ci-C6-alkylene, Ci-C6-alkyloxy-C3-C6- alkenylene, d-Ce-alkyloxy-Cs-Cβ-alkynylene, Ci-C6-alkyloxyphenyl-Ci- C6-alkylene, phenyloxy-Ci-C6-alkylene, Ci-C6-alkylamino, di(Ci-C6-alkyl)amino, Ci-C6-alkylamino-Ci-C6- alkylene, di(Ci-C6)-alkylamino-Ci-C6-alkylene, C3-C7-cycloalkyl-(C0-C6- alkyl)amino,
C1-C6-acyl-(Co-C6-alkyl)amido, Ci-Ce-alkylaminocarbonyl, di(C1-C6- alkyl)aminocarbonyl, (C3-C7-cycloalkyl)aminocarbonyl, di(C3-C7- cycloalky^aminocarbonyl, C3-C7-cycloalkyl-C1-C6-alkyleneamino- carbonyl,
Ci-C6-alkylcarbonyl, C3-C7-cycloalkylcarbonyl, carboxy, carboxamido [-C(O)NH2], Ci-Cβ-alkyloxycarbonyl, Ci-C3-alkylsulphanyl, d-C6-alkysulphonyl, C3-C7-cycloalkylsulphonyl, C3-C7-cycloalkyl-Ci-C6-alkylenesulphonyl,
Ci-C6-alkylaminosulphonyl, di(Ci-C6-alkyl)aminosulphonyl, (C3-C7- cycloalkyl)aminosulphonyl, di(C3-C7-cycloalkyl)aminosulphonyl, C3-C7- cycloalkyl-Ci-C6-alkyleneaminosulphonyl, d-C6-alkylsulphonylamido, -N(C0-C6-alkyl)-C(O)-Ci-C6-alkyl, -N(C0-C6-alkyl)-C(O)-C3-C7-cycloalkyl, -N(Co-C6-alkyl)-C(0)-N-di(Co-C6-alkyl), -N(C0-C6-alkyl)-C(O)-O-(C0-
C6)alkyl, -N(C0-C6-alkyl)-C(O)-NH-C3-C7-cycloalkyl, -N(Co-C6-alkyl)-Sθ2-Ci-C6-alkyl, -N(C0-C6-alkyl)-SO2-C3-C7-cycloalkyl, -N(C0-C6-alkyl)-S02-N-di(Co-C6-alkyl), -N(C0-C6-alkyl)-SO2-NH-(C3-C7)- cycloalkyl, -CCOJ-NCHJ-Cz-Cβ-alkylene-CCi-Cβ-alkyOamine, -C(O)-N(H)-C2-C6- alkylene-[di(C1-C6-alkyl)]amine, -C(O)-N(H)-C2-C6-alkylene-(C3-C7- cycloalkyl)amine, -C(O)-N(H)-C2-C6-alkylene-(C3-C7-cycloalkyl-C1-C6- alkyl)amine, -S(O2)-N(H)-C2-C6-alkylene-(Ci-C6-alkyl)amine, -S(O2)-N(H)-C2-C6- alkylene-[di(Ci-C6-alkyl)]amine, -S(O2)-N(H)-C2-C6-alkylene-(C3-C7- cycloalkyl)amine, -S(O2)-N(H)-C2-C6-alkylene-(C3-C7-cycloalkyl-CrC6- alkylene)amine,
-O-C2-C6-alkylene-(Ci-C6-alkyl)amine, -O-C2-C6-alkylene-[di(Ci-C6- alkylene)]amine,
(Ci-C6-alkyl)oxy-C2-C6-alkylene-aminocarbonyl, carboxy-Ci-Ce-alkylene-carbonylamido, (Ci-C6-alkyl)sulfonylmido, or the radicals:
Figure imgf000007_0001
Figure imgf000008_0001
R3 and R4 may together form heterocycloalkyl, cycloalkyl;
Q is an aryl or heteroaryl group or the group
Figure imgf000009_0001
in which A is a monocyclic aryl or a monocyclic heteroaryl group;
V is a cycloalkylen, cycloalkenylen, heterocycloalkylen or heterocycloalkenylen group;
X is a bond or an ethinylen group; W is an aryl or heteroaryl group;
where
R1 substitutes one or more positions of the aryl or heteroaryl ring in the indole residue;
R2 substitutes one or more positions of the aryl or heteroaryl ring in the radical Q and or the radical V.
The present invention relates to both possible enantiomeric forms at the stereocentre of the tryptamine residue.
The unbranched C-i-Cβ-alkyl groups for the radicals R1 to R5 may be for example a methyl, ethyl, propyl, butyl, pentyl or a hexyl group; and the branched C3-C6-alkyl groups for the radicals R1 to R6 may be an /sopropyl, /sobutyl, sec-butyl, terf-butyl,
/sopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, neopenfyl, 1 ,1-dimethylpropyl, 4- methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1 ,1-dimethylbutyl, 2,3-dimethylbutyl, 1 ,3-dimethyl- butyl or a 1 ,2-dimethylbutyl group. The branched or unbranched C2-C6-alkenyl groups for the radical R2 to R5 may be for example a vinyl, allyl, (E)-2-methylvinyl, (Z)-2-methylvinyl, homoallyl, (£)-but-2-enyl, (Z)- but-2-enyl, (£)-but-1-enyl, (Z)-but-i-enyl, pent-4-enyl, (£)-pent-3-enyl, (Z)-pent-3-enyl, (£)-pent-2-enyl, (Z)-pent-2-enyl, (£)-pent-1-enyl, (Z)-pent-i-enyl, hex-5-enyl, (£)-hex-4- enyl, (Z)-hex-4-enyl, (£)-hex-3-enyl, (Z)-hex-3-enyl, (£)-hex-2-enyl, (Z)-hex-2-enyl, (£)- hex-1-enyl, (Z)-hex-i-enyl, isopropenyl, 2-methylprop-2-enyl, 1-methylprop-2-enyl, 2- methylprop-1-enyl, (£)-1-methylprop-1-enyl, (Z)-1-methylprop-1-enyl, 3-methylbut-3- enyl, 2-methylbut-3-enyl, 1-methylbut-3-enyl, 3-methylbut-2-enyl, (£)-2-methylbut-2- enyl, (Z)-2-methylbut-2-enyl, (£)-1-methylbut-2-enyl, (Z)-1-methylbut-2-enyl, (£)-3- methylbut-1-enyl, (Z)-3-methylbut-1-enyl, (£)-2-methylbut-1-enyl, (Z)-2-methylbut-1- enyl, (£)-1 -methylbut-1-enyl, (Z)- 1 -methylbut-1-enyl, 1 ,1-dimethylprop-2-enyl, 1-ethyl- prop-1-enyl, 1-propylvinyl, 1-isopropylvinyl, 4-methylpent-4-enyl, 3-methylpent-4-enyl, 2- methylpent-4-enyl, 1-methylpent-4-enyl, 4-methylpent-3-enyl, (£)-3-methylpent-3-enyl, (Z)-3-methylpent-3-enyl, (£)-2-methylpent-3-enyl, (Z)-2-methylpent-3-enyl, (£)-1-methyl- pent-3-enyl, (Z)-1-methylpent-3-enyl, (£)-4-methylpent-2-enyl, (Z)-4-methylpent-2-enyl, (£)-3-methylpent-2-enyl, (Z)-3-methylpent-2-enyl, (£)-2-methylpent-2-enyl, (Z)-2-methyl- pent-2-enyl, (£)-1-methylpent-2-enyl, (Z)-1-methylpent-2-enyl, (£)-4-methylpent-1-enyl, (Z)-4-methylpent-1-enyl, (£)-3-methylpent-1-enyl, (Z)-3-methylpent-1-enyl, (£)-2-methyl- pent-1-enyl, (Z)-2-methylpent-1-enyl, (£)-1-methylpent-1-enyl, (Z)-1-methylpent-1-enyl, 3-ethylbut-3-enyl, 2-ethylbut-3-enyl, 1-ethylbut-3-enyl, (£)-3-ethylbut-2-enyl, (Z)-3-ethyl- but-2-enyl, (£)-2-ethylbut-2-enyl, (Z)-2-ethylbut-2-enyl, (£)-1-ethylbut-2-enyl, (Z)-1-ethyl- but-2-enyl, (£)-3-ethylbut-1-enyl, (Z)-3-ethylbut-1-enyl, 2-ethylbut-1-enyl, (£)-1-ethylbut- 1-enyl, (Z)-1-ethylbut-1-enyl, 2-propylprop-2-enyl, 1-propylprop-2-enyl, 2-isopropylprop- 2-enyl, 1-isopropylprop-2-enyl, (£)-2-propylprop-1-enyl, (Z)-2-propylprop-1-enyl, (£)-1- propylprop-1-enyl, (Z)-1-propylprop-1-enyl, (£)-2-isopropylprop-1-enyl, (Z)-2-isopropyl- prop-1-enyl, (£)-1-isopropylprop-1-enyl, (Z)-1-isopropylprop-1-enyl, (£)-3,3-dimethyl- prop-1-enyl, (Z)-3,3-dimethylprop-1-enyl- or a 1-(1 ,1-dimethylethyl)ethenyl group.
The Cs-Cβ-alkynyl groups for the radicals R2 to R5 may be for example an ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, 1- methylprop-2-ynyl, 2-methylbut-3-ynyl, 1-methylbut-3-ynyl, 1-methylbut-2-ynyl, 3- methylbut-1-ynyl, 1-ethylprop-2-ynyl, 3-methylpent-4-ynyl, 2-methylpent-4-ynyl, 1- methylpent-4-ynyl, 2-methylpent-3-ynyl, 1-methylpent-3-ynyl, 4-methylpent-2-ynyl, 1- methylpent-2-ynyl, 4-methylpent-1-ynyl, 3-methylpent-1-ynyl, 2-ethy I but-3-ynyl, 1 -ethylbut-3-ynyl, 1 -ethyl but-2-ynyl, 1-propylprop-2-ynyl, 1-isopropylprop-2-ynyl, 2,2- dimethylbut-3-ynyl, 1 ,1-dimethylbut-3-ynyl, 1 ,1-dimethylbut-2-ynyl or a 3,3-dimethylbut- 1-ynyl group.
The Ci-C6-alkyloxy groups for the radicals R2 to R5 may be for example a methyloxy, ethyloxy, propyloxy, /sopropyloxy, butyloxy, /sobutyloxy, sec-butyloxy, te/t-butyloxy, pentyloxy, /sopentyloxy, (2-methyl butyl )oxy, (i-methylbutyl)oxy, (i-ethylpropyl)oxy, neopentyloxy, (1 ,1-dimethylpropyl)oxy, hexyloxy, (4-methylpentyl)oxy, (3-methylpentyl)- oxy, (2-methyl pentyl)oxy, (i-methylpentyl)oxy, (i-ethylbutyl)oxy, (2-ethylbutyl)oxy, (3,3- dimethylbutyl)oxy, (2,2-dimethylbutyl)oxy, (1 ,1-dimethylbutyl)oxy, (2,3-dimethylbutyl)- oxy, (1 ,3-dimethylbutyl)oxy or a (1 ,2-dimethylbutyl)oxy group.
The halogens for the radicals R1 to R5 are fluorine, chlorine, bromine or iodine.
The Ci-C3-alkylsulphanyl groups for the radicals R3 to R5 may be for example a methylsulphanyl (CH3S-), ethylsulphanyl (CH3CH2S-), propylsulphanyl, /sopropyl- sulphanyl group.
The d-Ce-alkylaminocarbonyl groups for the radicals R3 to R5 may be for example a methylaminocarbonyl-, ethylaminocarbonyl-, propylaminocarbonyl-, /sopropylamino- carbonyl-, butylaminocarbonyl-, /sobutylaminocarbonyl-, sec-butylaminocarbonyl-, tert- butylaminocarbonyl-, pentylaminocarbonyl-, /sopentylaminocarbonyl-, (2-methylbutyl)- aminocarbonyl-, (i-methylbutyl)aminocarbonyl-, (i-ethylpropyl)aminocarbonyl-, neo- penfylaminocarbonyl-, (1 ,1-dimethylpropyl)aminocarbonyl-, hexylaminocarbonyl-, (4- methylpentyl)aminocarbonyl-, (3-methylpentyl)aminocarbonyl-, (2-methylpentyl)amino- carbonyl-, (i-methylpentyl)aminocarbonyl-, (i-ethylbutyl)aminocarbonyl-, (2-ethylbutyl)- aminocarbonyl-, (3,3-dimethylbutyl)aminocarbonyl-, (2,2-dimethylbutyl)aminocarbonyl-, (1 ,1-dimethylbutyl)aminocarbonyl-, (2,3-dimethylbutyl)aminocarbonyl-, (1 ,3-dimethyl- butyl)aminocarbonyl- or a (1 ,2-dimethylbutyl)aminocarbonyl group.
The hydroxy-Ci-Cβ-alkylene groups for the radicals R3 to R5 may be a hydroxymethyl (HOCH2-), 2-hydroxyethyl (HOCH2CH2-), 1-hydroxyethyl [CH3CH(OH)-], 3-hydroxy- propyl (HOCH2CH2CH2-), 2-hydroxypropyl [CH3CH(OH)CH2-], 1-hydroxypropyl [CH3CH2CH(OH)-], 2-hydroxy-1-methylethyl [HOCH2CH(CH3)-], 1-hydroxy-1-methyl- ethyl [(CHa)2C(OH)-], 4-hydroxybutyl (HOCH2CH2CH2CH2-), 3-hydroxybutyl [CH3CH(OH)CH2CH2-], 2-hydroxybutyl [CH3CH2CH(OH)CH2-], 1-hydroxybutyl [CH3CH2CH2CH(OH)-], 3-hydroxy-1-methylpropyl [HOCH2CH2CH(CH3)-], 2-hydroxy-1- methylpropyl [CH3CH(OH)CH(CH3)-], 1-hydroxy-1-methylpropyl [CH3CH2C(CH3)(OH)-], 1-(hydroxymethyl)propyl [CH3CH(CH2OH)-], 3-hydroxy-2-methylpropyl [HOCH2CH(CH3)CH2-], 2-hydroxy-2-methylpropyl [(CHs)2C(OH)CH2-], 1-hydroxy-2- methylpropyl [CH3CH(CH3)CH(OH)-] or a 2-hydroxy-1 , 1 -dimethylethyl group [HOCH2C(CH3)H.
The heterocycloalkyl groups which may form the radicals R3 and R4 together may be for example the following groups:
Figure imgf000012_0001
The cycloalkyl groups which may form the radicals R3 and R4 together may be for example the following groups:
Figure imgf000012_0002
The C3-C7-cycl oa Iky I groups for the radicals R2 to R5 may be for example a cyclopro- pyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl group. The C3-C7-heterocycloalkyl groups for the radicals R1 to R5 may be for example a cyclopropyl, cyclobutyl, cycopentyl, cyclohexyl, cycloheptyl group in which one or two carbon atoms of the ring are replaced independently of one another by an oxygen, nitrogen or sulphur atom. The monocyclic aryl group for A may be for example a phenyl group which is linked via substitutable positions.
The aryl group for W or Q may be for example a phenyl, naphthyl group which is linked via substitutable positions.
The monocylic heteroaryl group for A may be for example a pyridinyl, pyrimidinyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, pyrrolyl, pyrazolyl or an imidazolyl group which is linked via substitutable positions.
The heteroaryl group for W or Q may be for example a pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, 1.5-naphthyridinyl, 1 ,6- naphthyridinyl, 1 ,7-naphthyridinyl, 1 ,8-naphthyridinyl, benzofuranyl, benzothienyl, 1 ,3- benzodioxolyl, 2,1 ,3-benzothiadiazolyl, indolyl, indazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, pyrrolyl, pyrazolyl or an imidazolyl group which is linked via substitutable positions.
The heterocycloalkylen groups for V may be for example the following groups:
Figure imgf000014_0001
The heterocycloalkenylen groups for V may be for example the following groups:
Figure imgf000015_0001
The cycloalkylen groups for V may be for example the following groups:
Figure imgf000015_0002
The cycloalkenylen groups for V may be for example the following groups:
Figure imgf000015_0003
The C3-C7-cycloalkyloxy groups for the radicals R2 to R5 may be for example a cyclo- propyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy group. The d-Ce-alkylamino groups for the radicals R1 to R6 may be for example methyl- amino, ethylamino, propylamine /sopropylamino, butylamino, /sobutylamino, sec-butyl- amino, te/t-butylamino, pentylamino, /sopentylamino, (2-methylbutyl)amino, (1-methyl- butyl)amino, (i-ethylpropyl)amino, neopentylamino, (1 ,1-dimethylpropyl)amino, hexyl- amino, (4-methylpentyl)amino, (3-methylpentyl)amino, (2-methylpentyl)amino, (i-methylpentyl)amino, (i-ethylbutyl)amino, (2-ethylbutyl)amino, (3,3-dimethylbutyl)- amino, (2,2-dimethylbutyl)amino, (1 ,1-dimethylbutyl)amino, (2,3-dimethylbutyl)amino, (1 ,3-dimethylbutyl)amino or a (1 ,2-dimethylbutyl)amino group.
In the di(Ci-C6-alkyl)amino groups for the radicals R3 to R5, each of the two radicals on the nitrogen atom of the dialkylamino group may be chosen independently of one another from the following radicals: possible examples are a methyl, ethyl, propyl, /sopro- pyl, butyl, /sobutyl, sec-butyl, terf-butyl, pentyl, /sopentyl, (2-methylbutyl), (1 -methyl- butyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3- methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-di- methylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethyl- butyl) or a (1 ,2-dimethylbutyl) group.
In the C3-C7-cycloalkyl-Ci-C6-alkyleneoxy groups for the radicals R2 to R5 it is possible to combine each of the C3-C7-cycloalkyl groups of the C3-C7-cycloalkyl-Ci-C6- alkyleneoxy group, for example of a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group, independently of one another with each C0-C6-alkyleneoxy group, for example with a methyleneoxy, ethyleneoxy, propyleneoxy, butyleneoxy, pentylene- oxy, hexyleneoxy group. In the hydroxy-C3-C6-alkenylene groups for the radicals R2 to R5 it is possible for the hydroxy group to be located on any desired position of the C3-C6-alkenyl group, for example of an allyl, (E)-2-methylvinyl, (Z)-2-methylvinyl, homoallyl, (£)-but-2-enyl, (Z)-but- 2-enyl, (E)-but-i-enyl, (Z)-but-i-enyl, pent-4-enyl, (£)-pent-3-enyl, (Z)-pent-3-enyl, (E)- Pent-2-enyl-, (Z)-Pent-2-enyl-, (E)-Pent-i-enyl-, (Z)-Pent-i-enyl-, hex-5-enyl-, (E)-hex- 4-enyl, (Z)-hex-4-enyl, (£)-hex-3-enyl, (Z)-hex-3-enyl, (£)-hex-2-enyl, (Z)-hex-2-enyl, (E)-hex-i-enyl, (Z)-hex-i-enyl, isopropenyl, 2-methylprop-2-enyl, 1-methylprop-2-enyl, 2-methylprop-1-enyl, (£)-1-methylprop-1-enyl, (Z)-1-methylprop-1-enyl, 3-methylbut-3- enyl, 2-methylbut-3-enyl, 1-methylbut-3-enyl, 3-methylbut-2-enyl, (E)-2-methylbut-2- enyl, (Z)-2-methylbut-2-enyl, (£)-1-methylbut-2-enyl, (Z)-1-methylbut-2-enyl, (E)-3- methylbut-1-enyl, (Z)-3-methylbut-1-enyl, (£)-2-methylbut-1-enyl, (Z)-2-methylbut-1- enyl, (£)-1 -methylbut-1-enyl, (Z)-1 -methylbut-1-enyl, 1 ,1-dimethylprop-2-enyl, 1-ethyl- prop-1-enyl, 1-propylvinyl, 1-isopropylvinyl, 4-methylpent-4-enyl, 3-methylpent-4-enyl, 2- methylpent-4-enyl, 1-methylpent-4-enyl, 4-methylpent-3-enyl, (£)-3-methylpent-3-enyl, (Z)-3-methylpent-3-enyl, (E)-2-methylpent-3-enyl, (Z)-2-methylpent-3-enyl, (E)-1-methyl- pent-3-enyl, (Z)-1-methylpent-3-enyl, (£)-4-methylpent-2-enyl, (Z)-4-methylpent-2-enyl, (£)-3-methylpent-2-enyl, (Z)-3-methylpent-2-enyl, (£)-2-methylpent-2-enyl, (Z)-2-methyl- pent-2-enyl, (£)-1-methylpent-2-enyl, (Z)-1-methylpent-2-enyl, (£)-4-methylpent-1-enyl, (Z)-4-methylpent-1-enyl, (£)-3-methylpent-1-enyl, (Z)-3-methylpent-1-enyl, (£)-2-methyl- pent-1-enyl, (Z)-2-methylpent-1-enyl, (£)-1-methylpent-1-enyl, (Z)-1-methylpent-1-enyl, 3-ethylbut-3-enyl, 2-ethylbut-3-enyl, 1-ethylbut-3-enyl, (£)-3-ethylbut-2-enyl, (Z)-3-ethyl- but-2-enyl, (£)-2-ethylbut-2-enyl, (Z)-2-ethylbut-2-enyl, (£)-1-ethylbut-2-enyl, (Z)-1-ethyl- but-2-enyl, (£)-3-ethylbut-1-enyl, (Z)-3-ethylbut-1-enyl, 2-ethylbut-1-enyl, (£)-1-ethylbut- 1-enyl, (Z)-1-ethylbut-1-enyl, 2-propylprop-2-enyl, 1-propylprop-2-enyl, 2-isopropylprop- 2-enyl, 1-isopropylprop-2-enyl, (£)-2-propylprop-1-enyl, (Z)-2-propylprop-1-enyl, (£)-1- propylprop-1-enyl, (Z)-1-propylprop-1-enyl, (£)-2-isopropylprop-1-enyl, (Z)-2-isoprop- ylprop-1-enyl, (£)-1-isopropylprop-1-enyl, (Z)-1-isopropylprop-1-enyl, (£)-3,3-dimethyl- prop-1-enyl, (Z)-3,3-dimethylprop-1-enyl or a 1-(1 ,1-dimethylethyl)ethenyl group, and to be combined independently of one another. In the hydroxy-C3-C6-alkynyl groups for the radicals R2 to R5 it is possible for the hy- droxy group to be located at any desired position of the C3-C6-alkynyl group, for example of a prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, pent-1-ynyl, pent-2- ynyl, pent-3-ynyl, pent-4-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, 1-methylprop-2-ynyl, 2-methylbut-3-ynyl, 1-methylbut-3-ynyl, 1-methylbut-2-ynyl, 3- methylbut-1-ynyl, 1-ethylprop-2-ynyl, 3-methylpent-4-ynyl, 2-methylpent-4-ynyl, 1- methylpent-4-ynyl, 2-methylpent-3-ynyl, 1-methylpent-3-ynyl, 4-methylpent-2-ynyl, 1-methylpent-2-ynyl, 4-methylpent-1-ynyl, 3-methylpent-1-ynyl, 2-ethylbut-3-ynyl, 1 -ethyl but-3-ynyl, 1 -ethyl but-2-ynyl, 1-propylprop-2-ynyl, 1-isopropylprop-2-ynyl, 2,2-di- methylbut-3-ynyl, 1 ,1-dimethylbut-3-ynyl, 1 ,1-dimethylbut-2-ynyl or a 3,3-dimethylbut-1- ynyl group. In the CrC6-alkyloxy-C3-C6-alkenylene groups for the radicals R2 to R5 it is possible for the Ci-C6-alkyloxy group, for example a methyloxy, ethyloxy, propyloxy, /sopropyloxy, butyloxy, /sobutyloxy, sec-butyloxy, terf-butyloxy, pentyloxy, /sopentyloxy, (2-methyl- butyl)oxy, (i-methylbutyl)oxy, (i-ethylpropyl)oxy, neopentyloxy, (1 ,1-dimethylpropyl)oxy, hexyloxy, (4-methylpentyl)oxy, (3-methylpentyl)oxy, (2-methylpentyl)oxy, (1-methyl- pentyl)oxy, (i-ethylbutyl)oxy, (2-ethylbutyl)oxy, (3,3-dimethylbutyl)oxy, (2,2-dimethyl- butyl)oxy, (1 ,1-dimethylbutyl)oxy, (2,3-dimethylbutyl)oxy, (1 ,3-dimethylbutyl)oxy or a (1 ,2-dimethylbutyl)oxy group, to be located on any desired position of the C3-C6-alkenyl group, for example of an allyl, (£)-2-methylvinyl, (Z)-2-methylvinyl, homoallyl, (£)-but-2- enyl, (Z)-but-2-enyl, (£)-but-1-enyl, (Z)-but-i-enyl, pent-4-enyl, (£)-pent-3-enyl, (Z)- pent-3-enyl, (£)-pent-2-enyl, (Z)-pent-2-enyl, (£)-pent-1-enyl, (Z)-pent-i-enyl, hex-5-enyl, (£)-hex-4-enyl, (Z)-hex-4-enyl, (£)-hex-3-enyl, (Z)-hex-3-enyl, (£)-hex-2- enyl, (Z)-hex-2-enyl, (£)-hex-1-enyl, (Z)-hex-i-enyl, isopropenyl, 2-methylprop-2-enyl, 1-methylprop-2-enyl, 2-methylprop-1-enyl, (£)-1-methylprop-1-enyl, (Z)-1-methylprop-1- enyl, 3-methylbut-3-enyl, 2-methylbut-3-enyl, 1-methylbut-3-enyl, 3-methylbut-2-enyl, (£)-2-methylbut-2-enyl, (Z)-2-methylbut-2-enyl, (£)-1-methylbut-2-enyl, (Z)-i-methylbut- 2-enyl, (£)-3-methylbut-1-enyl, (Z)-3-methylbut-1-enyl, (£)-2-methylbut-1-enyl, (Z)-2- methylbut-1-enyl, (£)-1-methylbut-1-enyl, (Z)-1-methylbut-1-enyl, 1 ,1-dimethylprop-2- enyl, 1-ethylprop-1-enyl, 1-propylvinyl, 1-isopropylvinyl, 4-methylpent-4-enyl, 3-methyl- pent-4-enyl, 2-methylpent-4-enyl, 1-methylpent-4-enyl, 4-methylpent-3-enyl, (E)-3-methylpent-3-enyl, (Z)-3-methylpent-3-enyl, (£)-2-methylpent-3-enyl, (Z)-2-methyl- pent-3-enyl, (E)-1-methylpent-3-enyl, (Z)-1-methylpent-3-enyl, (£)-4-methylpent-2-enyl, (Z)-4-methylpent-2-enyl, (£)-3-methylpent-2-enyl, (Z)-3-methylpent-2-enyl, (£)-2-methyl- pent-2-enyl, (Z)-2-methylpent-2-enyl, (£)-1-methylpent-2-enyl, (Z)-1-methylpent-2-enyl, (£)-4-methylpent-1-enyl, (Z)-4-methylpent-1-enyl, (£)-3-methylpent-1-enyl, (Z)-3-methyl- pent-1-enyl, (E)-2-methylpent-1-enyl, (Z)-2-methylpent-1-enyl, (£)-1-methylpent-1-enyl, (Z)-1-methylpent-1-enyl, 3-ethylbut-3-enyl, 2-ethylbut-3-enyl, 1-ethylbut-3-enyl, (£)-3- ethylbut-2-enyl, (Z)-3-ethylbut-2-enyl, (£)-2-ethylbut-2-enyl, (Z)-2-ethylbut-2-enyl, (£)-1- ethylbut-2-enyl, (Z)-1-ethylbut-2-enyl, (£)-3-ethylbut-1-enyl, (Z)-3-ethylbut-1-enyl, 2- ethylbut-1-enyl, (£)-1-ethylbut-1-enyl, (Z)-1-ethylbut-1-enyl, 2-propylprop-2-enyl, 1-propylprop-2-enyl, 2-isopropylprop-2-enyl, 1-isopropylprop-2-enyl, (£)-2-propylprop-1- enyl, (Z)-2-propylprop-1-enyl, (£)-1-propylprop-1-enyl, (Z)-1-propylprop-1-enyl, (£)-2- isopropylprop-1-enyl, (Z)-2-isopropylprop-1-enyl, (£)-1-isopropylprop-1-enyl, (Z)-1- isopropylprop-1-enyl, (£)-3,3-dimethylprop-1-enyl, (Z)-3,3-dimethylprop-1-enyl or a 1-(1 ,1-dimethylethyl)ethenyl group and to be combined independently of one another.
In the Ci-C6-alkyloxy-C3-C6-alkynylene groups for the radicals R2 to R5 it is possible for the Ci-C6-alkyloxy group, for example a methyloxy, ethyloxy, propyloxy, /sopropyloxy, butyloxy, /sobutyloxy, sec-butyloxy, terf-butyloxy, pentyloxy, /sopentyloxy, (2-methyl- butyl)oxy, (i-methylbutyl)oxy, (i-ethylpropyl)oxy, neopentyloxy, (1 ,1-dimethylpropyl)oxy, hexyloxy, (4-methylpentyl)oxy, (3-methylpentyl)oxy, (2-methylpentyl)oxy, (1-methyl- pentyl)oxy, (i-ethylbutyl)oxy, (2-ethylbutyl)oxy, (3,3-dimethylbutyl)oxy, (2,2-dimethyl- butyl)oxy, (1 ,1-dimethylbutyl)oxy, (2,3-dimethylbutyl)oxy, (1 ,3-dimethylbutyl)oxy or a (1 ,2-dimethylbutyl)oxy group, to be located at any desired position of the C3-C6-alkynyl group, for example of a prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, pent- 1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, 1-methylprop-2-ynyl, 2-methylbut-3-ynyl, 1-methylbut-3-ynyl, 1- methylbut-2-ynyl, 3-methylbut-1-ynyl, 1 -ethyl prop-2-ynyl, 3-methylpent-4-ynyl, 2-methylpent-4-ynyl, 1-methylpent-4-ynyl, 2-methylpent-3-ynyl, 1-methylpent-3-ynyl, 4-methylpent-2-ynyl, 1-methylpent-2-ynyl, 4-methylpent-1-ynyl, 3-methylpent-1-ynyl, 2-ethylbut-3-ynyl, 1 -ethyl but-3-ynyl, 1 -ethylbut-2-ynyl, 1-propylprop-2-ynyl,
1-isopropylprop-2-ynyl, 2,2-dimethylbut-3-ynyl, 1 ,1-dimethylbut-3-ynyl, 1 ,1-dimethylbut- 2-ynyl or a 3,3-dimethylbut-1-ynyl group, and to be combined independently of one another. In the C3-C7-cycloalkyl-(Co-C6)-alkyleneamino groups of the radicals R2 to R5 it is pos- sible for each of the C3-C7-cycloalkyl groups of the C3-C7-cycloalkyl-(C0-C6)-alkylene- amino group, for example of a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclo- heptyl group, to be combined independently of one another with each Co-Cβ-alkylene group, for example with a bond, a methylene, ethylene, propylene, butylene, pentylene, hexylene group. In the Ci-Cβ-alkyloxy-d-Ce-alkylene groups for the radical R2 to R5, it is possible for the Ci-Cβ-alkyloxy group to be selected independently for example from methyloxy, ethyloxy, propyloxy, /sopropyloxy, butyloxy, /sobutyloxy, sec-butyloxy, terf-butyloxy, pentyloxy, /sopentyloxy, (2-methyl butyl )oxy, (i-methylbutyl)oxy, (i-ethylpropyl)oxy, neopentyloxy, (1 ,1-dimethylpropyl)oxy, hexyloxy, (4-methylpentyl)oxy, (3-methylpentyl)- oxy, (2-methylpentyl)oxy, (i-methylpentyl)oxy, (i-ethylbutyl)oxy, (2-ethylbutyl)oxy, (3,3- dimethylbutyl)oxy, (2,2-dimethylbutyl)oxy, (1 ,1-dimethylbutyl)oxy, (2,3-dimethylbutyl)- oxy, (1 ,3-dimethylbutyl)oxy or a (1 ,2-dimethylbutyl)oxy and to be combined independently of one another with Ci-Cβ-alkylene groups such as, for example, methylene, ethylene, propylene, butylene, pentylene, hexylene. In the di(Ci-C6-alkyl)amino-C-i-C6-alkylene group for the radicals R3 to R5 it is possible for each of the two radicals on the nitrogen atom of the amino group to be selected independently for example from methyl, ethyl, propyl, /sopropyl, butyl, /sobutyl, sec-butyl, terf-butyl, pentyl, /sopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1- methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1- dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethylbutyl) group, and to be combined with d-C6-alkylene groups such as, for example, methylene, ethylene, propylene, butylene, pentylene, hexylene. The C3-C7-cycloalkyl-Ci-C6-alkylene groups for the radicals R2 to R5 may be for exam- pie a cyclopropyloxymethylene, cyclopropyloxyethylene, cyclopropyloxypropylene, cyclopropyloxybutylene, cyclopropyloxypentylene, cyclopropyloxyhexylene, cyclobuty- loxymethylene, cyclobutyloxyethylene, cyclobutyloxypropylene, cyclobutyloxybutylene, cyclobutyloxypentylene, cyclobutyloxyhexylene, cyclopentyloxymethylene, cyclopenty- loxyethylene, cyclopentyloxypropylene, cyclopentyloxybutylene, cyclopentyloxypenty- lene, cyclopentyloxyhexylene, cyclohexyloxymethylene, cyclohexyloxyethylene, cyclo- hexyloxypropylene, cyclohexyloxybutylene, cyclohexyloxypentylene, cyclohexyloxy- hexylene, cycloheptyloxymethylene, cycloheptyloxyethylene, cycloheptyloxypropylene, cycloheptyloxybutylene, cycloheptyloxypentylene, cycloheptyloxyhexylen group. In the Ci-C6-alkylamino-Ci-C6-alkylene groups for the radicals R2 to R5 it is possible for the Ci-C6-alkylamino group to be selected independently for example from methyl- amino, ethylamino, propylamine /sopropylamino, butylamino, /sobutylamino, sec-butyl- amino, te/t-butylamino, pentylamino, /sopentylamino, (2-methylbutyl)amino, (1-methyl- butyl)amino, (i-ethylpropyl)amino, neopenfylamino, (1 ,1-dimethylpropyl)amino, hexyl- amino, (4-methylpentyl)amino, (3-methylpentyl)amino, (2-methylpentyl)amino, (1- methylpentyl)amino, (i-ethylbutyl)amino, (2-ethylbutyl)amino, (3,3-dimethylbutyl)amino, (2,2-dimethylbutyl)amino, (1 ,1-dimethylbutyl)amino, (2,3-dimethylbutyl)amino, (1 ,3-di- methylbutyl)amino or a (1 ,2-dimethylbutyl)amino and to be combined with CrC6- alkylene groups such as, for example, methylene, ethylene, propylene, butylene, penty- lene, hexylene. In the C1-C6-acyl-(Co-C6-alkyl)amido groups for the radicals R3 to R5, it is possible for each of the C1-C6-BCyI groups, for example a formyl, acetyl, propionyl, 2-methylpro- pionyl, 2,2-dimethylpropionyl, butyryl, 2-methylbutyryl, 3-methylbutyryl, 2,2-dimethyl- butyryl, 2-ethylbutyryl, pentanoyl, 2-methylpentanoyl, 3-methylpentanoyl, 4-methyl- pentanoyl or a hexanoyl group, to be combined independently of one another with each (C0-C6-alkyl)amido group, for example a hydrogen atom, a methylamido, ethylamido, propylamido, isopropylamido, butylamido, isobutylamido, sec-butylamido, tert-butyl- amido, pentylamido, isopentylamido, (2-methylbutyl)amido, (i-methylbutyl)amido, (1- ethylpropyl)amido, neopentylamido, (1 ,1-dimethylpropyl)amido, hexylamido, (4-methyl- pentyl)amido, (3-methylpentyl)amido, (2-methylpentyl)amido, (i-methylpentyl)amido, (i-ethylbutyl)amido, (2-ethylbutyl)amido, (3,3-dimethylbutyl)amido, (2,2-dimethylbutyl)- amido, (1 ,1-dimethylbutyl)amido, (2,3-dimethylbutyl)amido, (1 ,3-dimethylbutyl)amido or a (1 ,2-dimethylbutyl)amido group.
The Ci-C6-alkylaminocarbonyl groups for the radicals R3 to R5 may be for example a methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylamino- carbonyl, butylaminocarbonyl, isobutylaminocarbonyl, sec-butylaminocarbonyl, tert-butylaminocarbonyl, pentylaminocarbonyl, isopentylaminocarbonyl, (2-methylbutyl)- aminocarbonyl, (i-methylbutyl)aminocarbonyl, (i-ethylpropyl)aminocarbonyl, neopen- tylaminocarbonyl, (1 ,1-dimethylpropyl)aminocarbonyl, hexylaminocarbonyl, (4-methyl- pentyl)aminocarbonyl, (3-methylpentyl)aminocarbonyl, (2-methylpentyl)aminocarbonyl, (i-methylpentyl)aminocarbonyl, (i-ethylbutyl)aminocarbonyl, (2-ethylbutyl)amino- carbonyl, (3,3-dimethylbutyl)aminocarbonyl, (2,2-dimethylbutyl)aminocarbonyl, (1 ,1- dimethylbutyl)aminocarbonyl, (2,3-dimethylbutyl)aminocarbonyl, (1 ,3-dimethylbutyl)- aminocarbonyl or a (1 ,2-dimethylbutyl)aminocarbonyl group. In the di(Ci-C6-alkyl)aminocarbonyl groups for the radicals R3 to R5, each of the two CrCβ-alkyl radicals on the nitrogen atom of the di(CrC6-alkyl)aminocarbonyl group may be independently of one another for example a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethyl- propyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2- methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-di- methylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-di- methylbutyl) group.
The (C3-C7-cycloalkyl)aminocarbonyl groups for the radicals R3 to R5 may be for example a cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocar- bonyl, cyclohexylaminocarbonyl or cycloheptylaminocarbonyl group.
In the di(C3-C7-cycloalkyl)aminocarbonyl groups for the radicals R3 to R5, each of the two C3-C7-cycloalkyl radicals on the nitrogen atom of the di(C3-C7-cycloalkyl)amino- carbonyl group may be independently of one another for example a cyclopropyl, cyclo- butyl, cyclopentyl, cyclohexyl or cycloheptyl group. In the C3-C7-cycloalkyl-Ci-C6-alkyleneaminocarbonyl groups of the radicals R3 to R5 it is possible for each of the C3-C7-cycloalkyl groups of the C3-C7-cycloalkyl-Ci-C6-alkyl- eneaminocarbonyl groups, for example of a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group, to be combined independently of one another with each d- C6-alkyleneaminocarbonyl group, for example with a methyleneaminocarbonyl, ethyl- eneaminocarbonyl, propyleneaminocarbonyl, butyleneaminocarbonyl, pentylene- aminocarbonyl, hexyleneaminocarbonyl group.
The Ci-C6-alkylcarbonyl groups for the radicals R3 to R5 may be for example a methyl- carbonyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl, isobutylcar- bonyl, sec-butylcarbonyl, tert-butylcarbonyl, pentylcarbonyl, isopentylcarbonyl, (2- methylbutyl)carbonyl, (i-methylbutyl)carbonyl, (i-ethylpropyl)carbonyl, neopentylcarbonyl, (1 ,1-dimethylpropyl)carbonyl, hexylcarbonyl, (4-methylpentyl)car- bonyl, (3-methylpentyl)carbonyl, (2-methylpentyl)carbonyl, (i-methylpentyl)carbonyl, (1- ethylbutyl)carbonyl, (2-ethylbutyl)carbonyl, (3,3-dimethylbutyl)carbonyl, (2,2-dimethyl- butyl)carbonyl, (1 ,1-dimethylbutyl)carbonyl, (2,3-dimethylbutyl)carbonyl, (1 ,3-dimethyl- butyl)carbonyl or a (1 ,2-dimethylbutyl)carbonyl group.
The C3-C7-cycloalkylcarbonyl groups for the radicals R3 to R5 may be for example a cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl or cycloheptylcarbonyl group. The Ci-C6-alkyloxycarbonyl groups for the radicals R3 to R5 may be for example a me- thyloxycarbonyl, ethyloxycarbonyl, propyloxycarbonyl, isopropyloxycarbonyl, butyloxy- carbonyl, isobutyloxycarbonyl, sec-butyloxycarbonyl, tert-butyloxycarbonyl, pentyloxy- carbonyl, isopentyloxycarbonyl, (2-methylbutyl)oxycarbonyl, (i-methylbutyl)oxycarbonyl, (1 -ethylpropyl)oxycarbonyl, neopentyloxycarbonyl, (1 , 1 -dimethylpropyl)oxycarbonyl, hexyloxycarbonyl, (4-methylpentyl)oxycarbonyl, (3-methylpentyl)oxycarbonyl, (2-methyl- pentyl)oxycarbonyl, (i-methylpentyl)oxycarbonyl, (i-ethylbutyl)oxycarbonyl, (2-ethyl- butyl)oxycarbonyl, (3,3-dimethylbutyl)oxycarbonyl, (2,2-dimethylbutyl)oxycarbonyl, (1 ,1- dimethylbutyl)oxycarbonyl, (2,3-dimethylbutyl)oxycarbonyl, (1 ,3-dimethylbutyl)oxy- carbonyl or a (1 ,2-dimethylbutyl)oxycarbonyl group. The CrCe-alkylsulphonyl groups for the radicals R3 to R5 may be for example a me- thylsulphonyl, ethylsulphonyl, propylsulphonyl, isopropylsulphonyl, butylsulphonyl, iso- butylsulphonyl, sec-butylsulphonyl, tert-butylsulphonyl, pentylsulphonyl, isopentylsul- phonyl, (2-methylbutyl)sulphonyl, (i-methylbutyl)sulphonyl, (i-ethylpropyl)sulphonyl, neopentylsulphonyl, (1 ,1-dimethylpropyl)sulphonyl, hexylsulphonyl, (4-methylpentyl)- sulphonyl, (3-methylpentyl)sulphonyl, (2-methylpentyl)sulphonyl, (i-methylpentyl)sul- phonyl, (i-ethylbutyl)sulphonyl, (2-ethylbutyl)sulphonyl, (3,3-dimethylbutyl)sulphonyl, (2,2-dimethylbutyl)sulphonyl, (1 , 1 -dimethylbutyl)sulphonyl, (2,3-dimethylbutyl)sulphonyl, (1 ,3-dimethylbutyl)sulphonyl or a (1 ,2-dimethylbutyl)sulphonyl group. The C3-C7-cycloalkylsulphonyl groups for the radicals R3 to R5 may be for example a cyclopropylsulphonyl, cyclobutylsulphonyl, cyclopentylsulphonyl, cyclohexylsulphonyl or cycloheptylsulphonyl group.
In the C3-C7-cycloalkyl-Ci-C6-alkylenesulphonyl groups of the radicals R3 to R5 it is possible for each of the C3-C7-cycloalkyl groups of the C3-C7-cycloalkyl-Ci-C6-alkylene- sulphonyl groups, for example of a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group, to be combined independently of one another with each d-C6-alkyl- enesulphonyl group, for example with a methylenesulphonyl, ethylenesulphonyl, propyl- enesulphonyl, butylenesulphonyl, pentylenesulphonyl, hexylenesulphonyl group. The C-rC6-alkylaminosulphonyl groups for the radicals R3 to R5 may be for example a methylaminosulphonyl, ethylaminosulphonyl, propylaminosulphonyl, isopropylaminosul- phonyl, butylaminosulphonyl, isobutylaminosulphonyl, sec-butylaminosulphonyl, tert- butylaminosulphonyl, pentylaminosulphonyl, isopentylaminosulphonyl, (2-methylbutyl)- aminosulphonyl, (i-methylbutyl)aminosulphonyl, (i-ethylpropyl)aminosulphonyl, neopentylaminosulphonyl, (1 , 1 -dimethylpropyl)aminosulphonyl, hexylaminosulphonyl, (4-methylpentyl)aminosulphonyl, (3-methylpentyl)aminosulphonyl, (2-methylpentyl)- aminosulphonyl, (i-methylpentyl)aminosulphonyl, (i-ethylbutyl)aminosulphonyl, (2- ethylbutyl)aminosulphonyl, (3,3-dimethylbutyl)aminosulphonyl, (2,2-dimethylbutyl)- aminosulphonyl, (1 ,1-dimethylbutyl)aminosulphonyl, (2,3-dimethylbutyl)aminosulphonyl, (1 ,3-dimethylbutyl)aminosulphonyl or a (1 ,2-dimethylbutyl)aminosulphonyl group. In the di(Ci-C6-alkyl)aminosulphonyl groups for the radicals R4 to R6, each of the two Ci-C6-alkyl radicals on the nitrogen atom of the di(CrC6-alkyl)aminosulphonyl group may be independently of one another for example a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1- ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2- dimethylbutyl) group. The (C3-C7-cycloalkyl)aminosulphonyl groups for the radicals R3 to R5 may be for example a cyclopropylaminosulphonyl, cyclobutylaminosulphonyl, cyclopentylaminosul- phonyl, cyclohexylaminosulphonyl or cycloheptylaminosulphonyl group. In the di(C3-C7-cycloalkyl)aminosulphonyl groups for the radicals R3 to R5, each of the two C3-C7-cycloalkyl radicals on the nitrogen atom of the di(C3-C7-cycloalkyl)amino- sulphonyl group may be independently of one another for example a cyclopropyl, cyclo- butyl, cyclopentyl, cyclohexyl or cycloheptyl group.
In the C3-C7-cycloalkyl-Ci-C6-alkyleneaminosulphonyl groups of the radicals R3 to R5, each of the C3-C7-cycloalkyl groups of the C3-C7-cycloalkyl-Ci-C6-alkyleneaminosul- phonyl groups, for example of a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group, can be combined independently of one another with each CrC6- alkyleneaminosulphonyl group, for example with a methyleneaminosulphonyl, ethyl- eneaminosulphonyl, propyleneaminosulphonyl, butyleneaminosulphonyl, pentyleneami- nosulphonyl, hexyleneaminosulphonyl group. The C-rC6-alkylsulphonylamido groups for the radicals R3 to R5 may be for example a methylsulphonylamido, ethylsulphonylamido, propylsulphonylamido, isopropylsulphon- ylamido, butylsulphonylamido, isobutylsulphonylamido, sec-butylsulphonylamido, tert- butylsulphonylamido, pentylsulphonylamido, isopentylsulphonylamido, (2-methylbutyl)- sulphonylamido, (i-methylbutyl)sulphonylamido, (i-ethylpropyl)sulphonylamido, neo- pentylsulphonylamido, (1 ,1-dimethylpropyl)sulphonylamido, hexylsulphonylamido, (4-methylpentyl)sulphonylamido, (3-methylpentyl)sulphonylamido, (2-methylpentyl)- sulphonylamido, (i-methylpentyl)sulphonylamido, (i-ethylbutyl)sulphonylamido, (2- ethylbutyl)sulphonylamido, (3,3-dimethylbutyl)sulphonylamido, (2,2-dimethylbutyl)- sulphonylamido, (1 ,1-dimethylbutyl)sulphonylamido, (2,3-dimethylbutyl)sulphonylamido, (1 ,3-dimethylbutyl)sulphonylamido or a (1 ,2-dimethylbutyl)sulphonylamido group. In the -N(C0-C6-alkyl)-C(O)-Ci-C6-alkyl groups of the radicals R3 to R5, each of the (C0-C6-alkyl) groups on the nitrogen atom of the -N(C0-C6-alkyl)-C(O)-Ci-C6-alkyl groups, for example a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methyl- pentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethyl- butyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethyl- butyl) group, may be combined independently of one another with each d-Ce-alkyl group on the carbonyl group of the amide, for example with a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3- methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethyl- butyl) or a (1 ,2-dimethylbutyl) group.
In the -N-(Co-C6-alkyl)-C(0)-C3-C7-cycloalkyl groups of the radicals R3 to R5, each of the (C0-C6-alkyl) groups on the nitrogen atom of the -N(C0-C6-alkyl)-C(O)-Ci-C6-alkyl groups, for example a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethyl- butyl) group, may be combined independently of one another with each C3-C7-cycloalkyl group on the carbonyl group of the amide, for example with a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group. In the -N(C0-C6-alkyl)-C(O)-N-di(C0-C6-alkyl) groups of the radicals R3 to R5, all three (C0-C6-alkyl) groups may be independently of one another a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3- dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-di- methylbutyl) or a (1 ,2-dimethylbutyl) group.
In the -N(Co-C6-alkyl)-C(0)-0-(Co-C6-alkyl) groups of the radicals R3 to R5, both (C0-C6-alkyl) groups may be independently of one another a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3- dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-di- methylbutyl) or a (1 ,2-dimethylbutyl) group. In the -N(C0-C6-alkyl)-C(O)-NH-(C3-C7-cycloalkyl) groups of the radicals R3 to R5, each of the (Co-Ce-alkyl) groups on the nitrogen atom of the -N(C0-C6-alkyl)-C(O)-NH-(C3-C7- cycloalkyl) groups, for example a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2- methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethylbutyl) group, may independently of one another be combined with each C3-C7- cycloalkyl group on the terminal nitrogen atom of the urea, for example with a cyclopro- pyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group.
In the -N(Co-C6-alkyl)-Sθ2-(Ci-C6-alkyl) groups of the radicals R3 to R5, each of the (C0-C6-alkyl) groups on the nitrogen atom of the -N(Co-C6-alkyl)-Sθ2-(Ci-C6-alkyl) group, for example a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethylbutyl) group, may independently of one another be combined with each CrCβ-alky! group on the sulphonyl group of the sulphonamide, for example with a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3- dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-di- methylbutyl) or a (1 ,2-dimethylbutyl) group. In the -N(Co-C6-alkyl)-Sθ2-C3-C7-cycloalkyl groups of the radicals R3 to R5, each of the (Co-Cβ-alkyl) groups on the nitrogen atom of the -N(C0-C6-alkyl)-Sθ2-C3-C7-cycloalkyl group, for example a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methyl- pentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethylbutyl) group, may be combined independently of one another with each C3-C7-cycloalkyl group on the sulphonyl group, for example with a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group. In the -N(C0-C6-alkyl)-Sθ2-N-di(Co-C6-alkyl) groups of the radicals R3 to R5, all three (C0-C6-alkyl) groups may be independently of one another a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3- dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethylbutyl) group.
In the -N(C0-C6-alkyl)-Sθ2-NH-(C3-C7)-cycloalkyl groups of the radicals R3 to R5, the C0-C6-alkyl group of the -N(Co-C6-alkyl)-Sθ2-NH-(C3-C7)-cycloalkyl group, for example a hydrogen, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pen- tyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1- ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethylbutyl) group, may be combined independently of one another with each C3-C7-cycloalkyl group, for example with a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group.
In the -C(O)-N(H)-C2-C6-alkylene-(Ci-C6-alkyl)amine groups of the radicals R3 to R5, each of the C2-C6-alkylene groups on the nitrogen atom of the -C(O)-N(H)-C2-C6-alkyl- ene-(Ci-C6-alkyl)amine group, for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each CrC6- alkyl group on the amino group, for example with a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1- ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2- dimethylbutyl) group.
In the -C(O)-N(H)-C2-C6-alkylene-[di(Ci-C6-alkyl)]amine groups of the radicals R3 to R5, each of the C2-C6-alkylene groups on the nitrogen atom of the -C(O)-N(H)-C2-C6- alkylene-[di(CrC6-alkyl)]amine group, for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each of the two identically or different Ci-C6-alkyl groups on the amino group, for example with a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl-, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-di- methylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethylbutyl) group.
In the -C(O)-N(H)-C2-C6-alkylene-(C3-C7-cycloalkyl)amine groups of the radicals R3 to R5, each of the (C2-C6-alkylene) groups of the -C(O)-N(H)-C2-C6-alkylene-(C3-C7-cyclo- alkyl)amine group, for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each C3-C7-cycloalkyl group on the amine, for example with a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group.
In the -C(O)-N(H)-C2-C6-alkylene-(C3-C7-cycloalkyl-C1-C6-alkylene)amine groups of the radicals R3 to R5, each of the (C2-C6-alkylene) groups of the -C(O)-N(H)-C2-C6- alkylene-(C3-C6-cycloalkyl-Ci-C6-alkylene)amine group, for example an ethylene, pro- pylene, butylene, pentylene or hexylene group, may be combined independently of one another with each C3-C7-cycloalkyl-Ci-C6-alkylene group on the amine, for example with a cyclopropylmethylene, cyclopropylethylene, cyclopropylpropylene, cyclopropylbuty- lene, cyclopropylpentylene, cyclopropylhexylene, cyclobutylmethylene, cyclobutylethyl- ene, cyclobutylpropylene, cyclobutylbutylene, cyclobutylpentylene, cyclobutylhexylene, cyclopentylmethylene, cyclopentylethylene, cyclopentylpropylene, cyclopentylhexylene, cyclohexylmethylene, cyclohexylethylene, cyclohexylpropylene, cyclohexylbutylene, cyclohexylpentylene, cyclohexylhexylene, cycloheptylmethylene, cycloheptylethylene, cycloheptylpropylene, cycloheptylbutylene, cycloheptylpentylene or cycloheptylhexylene group. In the -S(O2)-N(H)-C2-C6-alkylene-(C1-C6-alkyl)amine groups of the radicals R3 to R5, the (C2-C6-alkylene) groups of the -S(O2)-N(H)-C2-C6-alkylene-(C1-C6-alkyl)amine group, for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each d-Ce-alkyl group on the amino group, for example with a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert- butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1- dimethylpropyl), hexyl, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methyl- pentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-di- methylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethylbutyl) group. In the -S(O2)-N(H)-C2-C6-alkylene-[di(Ci-C6-alkyl)]amine groups of the radicals R4 to R6, the C2-C6-alkylene group of the -S(O2)-N(H)-C2-C6-alkylene-[di(Ci-C6-alkyl)]amine group, for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each of the two Ci-C6-alkyl groups on the amino group, for example with a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl-, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethylbutyl) group. In the -S(O2)-N(H)-C2-C6-alkylene-(C3-C7-cycloalkyl)amine groups of the radicals R3 to R5, the C2-C6-alkylene group of the -S(O2)-N(H)-C2-C6-alkylene-(C3-C7-cycloalkyl)- amine group, for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each C3-C7-cycloalkyl group on the amino group, for example with a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl group.
In the -S(O2)-N(H)-C2-C6-alkylene-(C3-C7-cycloalkyl-Ci-C6-alkylene)amine groups of the radicals R3 to R5, each C2-C6-alkylene group of the -S(O2)-N(H)-C2-C6-alkylene- (C3-C7-cycloalkyl-Ci-C6-alkylene)amine group, for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each C3-C7-cycloalkyl-Ci-C6-alkylene group on the amine, for example with a cyclo- propylmethylene, cyclopropylethylene, cyclopropylpropylene, cyclopropylbutylene, cyclopropylpentylene, cyclopropylhexylene, cyclobutylmethylene, cyclobutylethylene, cyclobutylpropylene, cyclobutylbutylene, cyclobutylpentylene, cyclobutylhexylene, cyclo- pentylmethylene, cyclopentylethylene, cyclopentylpropylene, cyclopentylhexylene, cyclohexylmethylene, cyclohexylethylene, cyclohexylpropylene, cyclohexylbutylene, cyclohexylpentylene, cyclohexylhexylene, cycloheptylmethylene, cycloheptylethylene, cycloheptylpropylene, cycloheptylbutylene, cycloheptylpentylen or cycloheptylhexylene group.
In the -O-C2-C6-alkylene-(C1-C6-alkyl)amine groups of the radicals R3 to R5, the C2-C6- alkylene group of the -O-C2-C6-alkylene-(Ci-C6-alkyl)amine group, for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with each d-C6-alkyl group on the amino group, for example a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, (2- methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1-dimethylpropyl), hexyl, (4- methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methylpentyl), (1-ethylbutyl), (2- ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethyl- butyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethylbutyl) group.
In the -O-C2-C6-alkylene-[di(Ci-C6-alkyl)]amine groups of the radicals R3 to R5, the C2- C6-alkylene group of the -O-C2-C6-alkylene-[di(Ci-C6-alkyl)]amine group, for example an ethylene, propylene, butylene, pentylene or hexylene group, may be combined independently of one another with two freely selectable CrCβ-alkyl groups on the amino group, for example with a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert- butyl, pentyl, isopentyl, (2-methylbutyl), (1-methylbutyl), (1-ethylpropyl), neopentyl, (1 ,1- dimethylpropyl), hexyl-, (4-methylpentyl), (3-methylpentyl), (2-methylpentyl), (1-methyl- pentyl), (1-ethylbutyl), (2-ethylbutyl), (3,3-dimethylbutyl), (2,2-dimethylbutyl), (1 ,1-dimethylbutyl), (2,3-dimethylbutyl), (1 ,3-dimethylbutyl) or a (1 ,2-dimethylbutyl) group.
Compounds preferred according to the present invention are those of the formulae and III
Figure imgf000030_0001
Figure imgf000030_0002
in which the radicals R1 to R5, X, W and V have the same meaning as defined in formula I. Compounds particularly preferred according to the present invention are those of the formula IV and V
Figure imgf000031_0001
Figure imgf000031_0002
in which the radicals R1 to R5, X, W and V have the same meaning as defined in formula I. The following compounds are very particularly preferred:
1 5'-Fluoro-4-isopropoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 3'-methylamide;
2 N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-5-(4-methylcarbamoyl-phenylethynyl)-2- trifluoromethoxy-benzamide;
3 3'-Chloro-4-isopropoxy-biphenyl-3,4'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 4'-methylamide;
4 5-(4-Carbamoyl-2-methylphenylethynyl)-N-[2-cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2- trifluoromethoxy-benzamide;
5 3'-Chloro-4-isopropoxy-biphenyl-3,4'-dicarboxylic acid 4'-amide 3-{[2-cyano-1-(1 H- indol-3-ylmethyl)-ethyl]-amide};
5 3'-Chloro-4-isopropoxy-4'-(morpholine-4-carbonyl)-biphenyl-3-carboxylic acid [2- cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-amide;
7 4-lsopropoxy-3',4'-dimethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
8 5-(4-Carbamoyl-phenylethynyl)-N-[2-cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2-isoprop- oxy-benzamide g N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2-isopropoxy-5-(4-methylcarbamoyl-phenyl- ethynyl)-benzamide;
I o N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2-isopropoxy-5-(3-methylcarbamoyl-phenyl- ethynyl)-benzamide;
I 1 N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2-isopropoxy-5-(2-methylcarbamoyl-phenyl- ethynyl)-benzamide;
12 4'-Morpholin-4-yl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide
13 4'-Methanesulfonylamino-methyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2- cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-amide;
14 N-{3'-[2-Cyano-1 -(1 H-indol-S-ylmethyO-ethylcarbamoyO-4'-trifluoromethoxy-biphenyl- 3-ylJ-succinamic acid;
4'-(Pyrrolidine-1-carbonyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1- (1 H-indol-3-ylmethyl)-ethyl]-amide;
N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-(1-methyl-1 H-indol-5-yl)-2- trifluoromethoxy-benzamide;
4-Trifluoromethoxy-biphenyl-3,4'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 4'-[(2-methoxy-ethyl)-amide];
3'-(Pyrrolidine-1-carbonyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1- (1 H-indol-3-ylmethyl)-ethyl]-amide;
4-Trifluoromethoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 3'-ethylamide;
4-Trifluoromethoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 3'-(isobutyl-amide);
4-Trifluoromethoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 3'-cyclopentylamide;
3'-(Methanesulfonylamino-methyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2- cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-amide;
4'-(Acetylamino-methyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H- indol-3-ylmethyl)-ethyl]-amide;
3'-(Acetylamino-methyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H- indol-3-ylmethyl)-ethyl]-amide;
4'-Methylsulfamoyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H- indol-3-ylmethyl)-ethyl]-amide;
3-Chloro-3'-[2-cyano-1 -(1 H-indol-3-ylmethyl)-ethylcarbamoyl]-4'-trifluoromethoxy- biphenyl-4-carboxylic acid methyl ester;
4'-Ethylsulfamoyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide; 3'-Chloro-4-trifluoromethoxy-biphenyl-3,4'-dicarboxylic acid 3-{[2-cyano-1 -(1 H-indol-3- ylmethyl)-ethyl]-amide} 4'-isopropylamide;
S'-Chloro-4-trifluoromethoxy-biphenyl-S^'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide} 4'-cyclopropylamide;
S'-Chloro-4-trifluoromethoxy-biphenyl-S^'-dicarboxylic acid 4'-tert-butylamide 3-{[2- cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-amide};
S'-Chloro-4-trifluoromethoxy-biphenyl-S^'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide} 4'-dimethylamide;
S'-Chloro-4-trifluoromethoxy-biphenyl-S^'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide} 4'-diethylamide;
3'-Chloro-4'-(morpholine-4-carbonyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2- cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-amide;
3'-Chloro-4'-(piperidine-1-carbonyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2- cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-amide;
3'-Chloro-4'-(pyrrolidine-1-carbonyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2- cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-amide;
5'-Ethoxy-3'-fluoro-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide;
5'-Fluoro-4-trifluoromethoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide} 3'-methylamide;
3'-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethylcarbamoyl]-3-methoxy-4'-trifluoromethoxy- biphenyl-4-carboxylic acid methyl ester;
S'-Fluoro-δ'-methoxy-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H- indol-3-ylmethyl)-ethyl]-amide;
4'-Acetylamino-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide; N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-5-quinolin-3-yl-2-trifluoromethoxy- benzamide;
3',5'-Dimethyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide;
4-Trifluoromethoxy-biphenyl-3,3'-dicarboxylic acid 3'-amide 3-{[2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide};
S'-Cyano-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
5-Benzo[1 ,3]dioxol-5-yl-N-[2-cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2-trifluoromethoxy- benzamide;
S'-Acetylamino-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide;
S'-Methanesulfonylamino-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1- (1 H-indol-3-ylmethyl)-ethyl]-amide;
4'-Chloro-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
2'-Methyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
2'-Fluoro-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
4-Trifluoromethoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 3'-methylamide;
N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-quinolin-6-yl-2-trifluoromethoxy- benzamide;
3'-Hydroxy-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide; 4-Trifluoromethoxy-4'-trifluoromethyl-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide;
S'-HydroxymethyM-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide;
4-Trifluoromethoxy-[1 ,1 ';3',1 "]terphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
3'-Fluoro-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
S'-Acetyl-^trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
3'-Amino-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
4'-Acetyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
4'-Methylsulfanyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide;
4-Trifluoromethoxy-3'-trifluoromethyl-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide;
4'-Hydroxy-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-naphthalen-1-yl-2-trifluoromethoxy- benzamide;
4'-Methyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
S'-Chloro-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide; N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-5-naphthalen-2-yl-2-trifluoromethoxy- benzamide;
S'-Methoxy-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
4'-Methoxy-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-thiophen-3-yl-2-trifluoromethoxy- benzamide.
Pharmacological Experiments HTRF assay for measuring cAMP in cells
The method is based on a competitive immunoassay between native cAMP, which has been produced by the cells, and cAMP which is labelled with cAMPD2 conjugate. The tracer binding was visualized by a monoclonal antibody, anti-cAMP labelled with cryptate [HTRF = homogeneous time-resolved fluorescence].
The specific signal is inversely proportional to the cAMP concentration of the samples employed.
The 665nm/ 620nm fluorescence ratio was evaluated.
The following material was used: 96-well plates for the tissue culture, 96-well plates with black edge and black base (e.g. Fluotrac 600 from Greiner), 96-well plates for the substance dilutions of polypropylene and cAMP Femtomolar (4000wells Kit, CIS Bio International # 62AM5PEJ).
The following reagents were used: BSA (bovine serum albumin) Fraction V protease- free, IBMX (3-isobutyl-1-methylxanthine), hFSH (human follicle stimulating hormone), Triton X-100 analytical grade, potassium fluoride analytical grade, G 418 (Geneticin) and Accutase.
Buffer 1 (washing and testing buffer) contained PBS, 1 mM CaCI2, 1 mM MgCI2, 0.2% glucose; 0.1% BSA, 1 mM IBMX.
Buffer 2 (2x lysis buffer) contained 1 % Triton X-100 in PBS (without CaCI2 and MgCI2).
Buffer 3 (assay buffer) contained 50 mM potassium phosphate buffer (pH 7.0); 800 mM potassium fluoride; 0.2% BSA (always added fresh).
Procedure:
On day 1 , the cells were seeded in 96-well plates (3x104 cells per well hFSHR clone 16 cells (CHO cells stably transfected with the human FSH receptor in 150 μl of medium). The next day, test substance dilutions were made up. For this purpose, all the substances were diluted in ice-cold buffer 1 (with or without hFSH), and the substance dilutions were placed on ice until applied to the cells.
The cell supernatant was then aspirated off, and the cells were washed 2x with 200 μl of buffer 1. The cells were treated with 60 μl of the appropriate substance concentrations at 370C for 2h. The cells were then lysed with 60 μl of buffer 2 (put onto the supernatant) (on a plate shaker at RT for 30 min).
The test conjugates (cAMP-D2 and anti-cAMP cryptate, CIS Bio) were diluted in buffer 3 in accordance with the manufacturers' information. The actual mixture for measurement was pipetted into a black 96-well plate (in each case 15 μl of the cell lysate diluted with 35 μl of buffer 1 ; firstly 25 μl of cAMP-D2 conjugate were pipetted and, after 10 min, 25 μl of the anti-cAMP cryptate were added). This is followed by incubation at RT for 90 minutes. The measurement was carried out in a PheraStar (BMG).
Tissue culture conditions
1 ) hFSHr clone 16 Ham's F12
PSG
10% FCS
700 μg/ml G 418 (Geneticin) from PAA.
Dose-effect curve (hFSH) for the human receptor: 1 e-8, 3e-9, 1 e-9, 3e-10, 1 e-10, 3e-
11 , 1 e-11 , 3e-12 mol/l.
The test substances were employed in suitable dilutions in the absence (test for agonism) and in the presence of 1 e-9 mol/l hFSH.
Evaluation
The values of the well ratio were averaged and then entered directly in SigmaPlot versus the concentrations. The maximum and minimum values were determined for each plate, and half the difference is to be regarded as IC50. The test results (Table 1 ) show that the compounds according to the invention have an
FSH-antagonistic effect. Table 1. FSH antagonistic effect of selected compounds in the HTRF assay
Figure imgf000040_0001
Being antagonists of the FSH receptor, compounds of the general formula I and their pharmaceutically acceptable salts can thus be used for the fertility control in male and/or in a female animals, in particular in men and/or women; as well as for the treatment and/or prevention of osteoporosis.
Pharmaceutical compositions
The invention further relates to compounds of the general formula I or pharmaceutically acceptable salts thereof as therapeutic active ingredients, and to pharmaceutical compositions comprising at least one compound of the general formula I or pharmaceutically acceptable salts thereof, where appropriate together with pharmaceutically suitable excipients and/or carriers.
Pharmaceutically acceptable salts of the compounds of the general formula I can be prepared by methods known to the skilled person, depending on the nature of the compound of formula I, either by using as inorganic acids inter alia hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid, nitric acid, as carboxylic acids inter alia acetic acid, propionic acid, hexanoic acid, octanoic acid, decanoic acid, oleic acid, stearic acid, maleic acid, fumaric acid, succinic acid, benzoic acid, ascorbic acid, oxalic acid, salicylic acid, tartaric acid, citric acid, lactic acid, glycolic acid, malic acid, mandelic acid, cinnamic acid, glutamic acid, aspartic acid, and as sulphonic acids inter alia methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid and naphthalenesulphonic acid; or by using an appropriate base as inorganic base inter alia alkalimetal hydroxide, carbonate, or hydrogencarbonate, as organic base inter alia tertiary amines and N- heterocycles.
These pharmaceutical compositions and medicaments may be intended for oral, rectal, subcutaneous, transdermal, percutaneous, intravenous or intramuscular administration. They comprise besides conventional carriers and/or diluents at least one compound of the general formula I. The medicaments of the invention are formulated using the customary solid or liquid carriers or diluents and the excipients customarily used in pharmaceutical technology, in accordance with the desired mode of administration with a suitable dosage in a known manner: i.e. by processing the active ingredient with the carrier substances, fillers, substances which influence disintegration, binders, humectants, lubricants, absorbents, diluents, test modifiers, colorants etc. which are used in pharmaceutical technology, and converting into the desired administration form. Reference should be made in this connection to Remington's Pharmaceutical Science, 15tn ed. Mack Publishing Company, East Pennsylvania (1980) and to Gennaro, A. R. et al., Remington: The Science and Practice of Pharmacy (20th Edition., Lippincott Williams & Wilkins 2000, see especially Part 5: Pharmaceutical Manufactoring). Pharmaceutical compositions according to the present invention are preferably administered orally. Suitable for oral administration are in particular tablets, (film)- coated tablets, sugar-coated tablets capsules, pills, powders, granules, pastilles, suspensions, emulsions, solutions or depot forms. Appropriate tablets can be obtained for example by mixing the active ingredient with known excipients, for example inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, disintegrants such as maize starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/ or agents to achieve a depot effect such as carboxylpolymethylene, carboxylmethylcellulose, cellulose acetate phthalate or polyvinyl acetate. The tablets may also consist of a plurality of layers.
Correspondingly, coated tablets can be produced by coating cores which have been produced in analogy to the tablets with agents normally used in tablet coatings, for example polyvinylpyrrolidone or shellac, gum Arabic, talc, titanium oxide or sugar. The tablet coating may also consist of a plurality of layers, it being possible to use the excipients mentioned above for tablets.
Solutions or suspensions with the compounds according to the invention of the general formula I may additionally comprise taste-improving agents such as saccharin, cyclamate or sugar and, for example, flavourings such as vanillin or orange extract. They may additionally comprise suspending aids such as sodium carboxymethylcellulose or preservatives such as p-hydroxybenzoates. Capsules comprising the compounds of the general formula I can be produced for example by the compound(s) of the general formula I being mixed with an inert carrier such as lactose or sorbitol and encapsulated in gelatine capsules.
Parenteral preparations such as solutions for injection are also suitable. Preparations for injection and infusion are possible for parenteral administration. Appropriately prepared crystal suspensions can be used for intraarticular injection. Aqueous and oily solutions for injection or suspensions and corresponding depot preparations can be used for intramuscular injection. The novel compounds can be used for rectal administration in the form of suppositories, capsules, solutions (e.g. in the form of enemas) and ointments both for systemic and for local therapy.
Suitable suppositories can be produced for example by mixing with carriers intended for this purpose, such as neutral fats or polyethylene glycol or derivatives thereof. Formulations suitable for topical application include gels, ointments, greasy ointments, creams, pastes, dusting powders, milk and tinctures. Topical use can also take place by means of a transdermal system, for example a patch. The concentration of the compounds of the general formula I in these preparations should typically be in the range of 0.01 % - 20% in order to achieve an adequate pharmacological effect.
The invention further relates to pharmaceutical compositions in combination with packaging material suitable for said composition, wherein said packaging material including instructions for the use of the composition.
Dose
Suitable doses for the compounds according to the present invention may vary from 0.005 mg to 50 mg per day per kg of body weight, depending on the age and constitution of the patient. It is possible to administer the necessary daily dose by single or multiple delivery. The preferred daily dose for larger mammals, for example humans, may vary in the range from 10 μg to 30 mg per kg of body weight. The exact dose and regimen of administration of the drug substance (active ingredient, or a pharmaceutical composition thereof, may however vary with the particular compound, the route of administration, and the age, sex and condition of the individual to whom the medicament is administered. The dose, the dosage as well as the regimen of the administration may thus differ between a male and a female considerably.
The present invention also relates to a process for preparing the compounds according to the invention. Compounds of the general formula I can be prepared as shown in Scheme 1 by an amide formation reaction between the amine Vl and the carboxylic acid VII. Reagents suitable for this purpose are all suitable peptide-coupling reagents which are known to the skilled person and which convert the carboxylic acid, where appropriate in the presence of a base, into an intermediate active ester, for example PyBOP ([(1 H-benzotriazol-1 -yl)oxy]tris(pyrrolidin-1 -yl)phosphonium hexafluorophos- phate), HATU (2-(7-aza-1 H-benzotriazol-1 -yl)-1 ,1 , 3, 3-tetramethyluronium hexafluoro- phosphate), HBTU (2-(1 H-benzotriazol-1 -yl)-1 , 1 ,3, 3-tetramethyluronium hexafluoro- phosphate), EDC (Λ/-[3-(dimethylamino)propyl]-Λ/'-ethylcarbodiimide hydrochloride) / HOBt (1-hydroxy-1 H-benzotriazole). It is possible as alternative for the carboxylic acid to be converted, where appropriate in the presence of a base, into the carbonyl chloride and reacted with the amine Vl to give the product of the general formula I.
Scheme 1
Figure imgf000044_0001
Compounds of the general formula Il can be prepared as shown in Scheme 2 by an amide formation reaction between the amine Vl and the carboxylic acid VIII. Reagents suitable for this purpose are all suitable peptide-coupling reagents which are known to the skilled person and which convert the carboxylic acid, where appropriate in the presence of a base, into an intermediate active ester, for example PyBOP ([(1 H-benzotriazol-1 -yl)oxy]tris(pyrrolidin-1-yl)phosphonium hexafluorophosphate), HATU (2-(7-aza- 1 H-benzotriazol-1 -yl)-1 , 1 ,3, 3-tetramethyluronium hexafluorophosphate), HBTU (2-(1 H- benzotriazol-1-yl)-1 , 1 ,3, 3-tetramethyluronium hexafluorophosphate), EDC (Λ/-[3-(di- methylamino)propyl]-Λ/'-ethylcarbodiimide hydrochloride) / HOBt (1-hydroxy-1 H-benzo- triazole). It is possible as alternative for the carboxylic acid to be converted, where appropriate in the presence of a base, into the carbonyl chloride and reacted with the amine Vl to give the product of the general formula II.
Scheme 2
Figure imgf000045_0001
Compounds of the general formula III can be prepared as shown in Scheme 3 by an amide formation reaction between the amine Vl and the carboxylic acid IX. Reagents suitable for this purpose are all suitable peptide-coupling reagents which are known to the skilled person and which convert the carboxylic acid, where appropriate in the presence of a base, into an intermediate active ester, for example PyBOP ([(1H-benzo- triazol-1-yl)oxy]tris(pyrrolidin-1-yl)phosphonium hexafluorophosphate), HATU (2-(7-aza- 1/-/-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate), HBTU (2-(1 H- benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate), EDC (Λ/-[3-(di- methylamino)propyl]-Λ/'-ethylcarbodiimide hydrochloride) / HOBt (1-hydroxy-1 H-benzo- triazole). It is possible as alternative for the carboxylic acid to be converted, where appropriate in the presence of a base, into the carbonyl chloride and reacted with the amine Vl to give the product of the general formula III.
Scheme 3
Figure imgf000045_0002
Compounds of the general formula IV can be prepared as shown in Scheme 4 by an amide formation reaction between the amine Vl and the carboxylic acid X. Reagents suitable for this purpose are all suitable peptide-coupling reagents which are known to the skilled person and which convert the carboxylic acid, where appropriate in the presence of a base, into an intermediate active ester, for example PyBOP ([(1H-benzo- triazol-1-yl)oxy]tris(pyrrolidin-1-yl)phosphonium hexafluorophosphate), HATU (2-(7-aza- 1H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate), HBTU (2-(1 H- benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate), EDC (Λ/-[3-(di- methylamino)propyl]-Λ/'-ethylcarbodiimide hydrochloride) / HOBt (1-hydroxy-1 H-benzo- triazole). It is possible as alternative for the carboxylic acid to be converted, where appropriate in the presence of a base, into the carbonyl chloride and reacted with the amine Vl to give the product of the general formula IV.
Scheme 4
Figure imgf000046_0001
Compounds of the general formula V can be prepared as shown in Scheme 5 by an amide formation reaction between the amine Vl and the carboxylic acid Xl. Reagents suitable for this purpose are all suitable peptide-coupling reagents which are known to the skilled person and which convert the carboxylic acid, where appropriate in the presence of a base, into an intermediate active ester, for example PyBOP ([(1H-benzotri- azol-1-yl)oxy]tris(pyrrolidin-1-yl)phosphonium hexafluorophosphate), HATU (2-(7-aza- 1H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate), HBTU (2-(1 H- benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate), EDC (Λ/-[3-(di- methylamino)propyl]-Λ/'-ethylcarbodiimide hydrochloride) / HOBt (1-hydroxy-1 H-benzo- triazole). It is possible as alternative for the carboxylic acid to be converted, where appropriate in the presence of a base, into the carbonyl chloride and reacted with the amine Vl to give the product of the general formula V. Scheme 5
Figure imgf000047_0001
Alternatively, compounds of the general formula I can also be prepared as shown in Scheme 6 by a metal catalyzed cross coupling reaction between the aryl halide XIII (wherein Hal stands for chlorine, bromine or iodine) and the correspondingly functionalized building block XII known to the skilled person, for example: a Suzuki reaction (R = -B(OH)2), a Sonogashira coupling (R = H, X = -C≡C-), a Negishi coupling (R = Zn-HaI) or a Stille coupling (R = Sn(alkyl)3). Preferred metal catalysts used are typically those containing palladium or nickel, depending on the nature of the cross- coupling reaction. For a more detailed description of the metal catalyzed cross-coupling reactions applied and applicable for the synthesis of compounds of the formula I, see e.g. S. Takahashi, Y. Kuroyama, K. Sonogashira and N. Hagihara, Synthesis, 1980, 627; Metal catalyzed Cross-coupling Reactions, ed. F. Diederich and P. J. Stang, Wiley- VCH, Weinheim, 1998; K. Sonogashira, J. Organomet. Chem., 2002, 653 (1-2), 46.
Scheme 6
Figure imgf000047_0002
Likewise, compounds of the general formula Il can be prepared as shown in Scheme 7 by a metal catalyzed cross coupling reaction between the aryl halide XIV and the correspondingly functionalized building block XII known to the skilled person.
Scheme 7
Figure imgf000048_0001
Likewise, compounds of the general formula III can be prepared as shown in Scheme 8 by a metal catalyzed cross coupling reaction between the aryl halide XV and the correspondingly functionalized building block XII known to the skilled person.
Scheme 8
Figure imgf000048_0002
Likewise, compounds of the general formula IV can be prepared as shown in Scheme 9 by a metal catalyzed cross coupling reaction between the aryl halide XVI and the correspondingly functionalized building block XII known to the skilled person. Scheme 9
Figure imgf000049_0001
Likewise, compounds of the general formula V can be prepared as shown in Scheme 10 by a metal catalyzed cross coupling reaction between the aryl halide XVII and the correspondingly functionalized building block XII known to the skilled person.
Scheme 10
Figure imgf000049_0002
Compounds of the general formula I can in principle be prepared as shown in Scheme 11 by an amide formation reaction between an amine Vl and a carboxylic acid VII. The reagents typically used for the coupling are EDCI and HOBt. Scheme 11
Figure imgf000050_0001
Reagents: a) EDCI, HOBt, triethylamine, DMF.
Compounds of the general formula Vl can be prepared according to scheme 12 starting from commercially available or literature known tryptophan derivatives XVIII. Esterification and subsequent reduction of the tryptophan esters XIX to the corresponding tryptophan s XX and subsequent double tosylation gives rise to compounds of formula XXI. After displacement of one tosyl group by a cyano group and deprotection of the tosyl amide one obtains the nitriles of general formula Vl.
Scheme 12
Figure imgf000050_0002
Reagents: a) SOCI2, MeOH; b) LiBH4, THF; c) LiAIH4, THF; d) TsCI, Pyridine; e) KCN, MeOH; f) Na, NH3. The carboxylic acid derivatives of formula XXXVIII can in principle be prepared according to Scheme 13 via a Sonogashira type coupling of acetylenes XXIII or XXVII with their corresponding aryl halides XXIV or XXVI with subsequent hydrolysis of the resulting carboxylic esters XXV.
Scheme 13
Figure imgf000051_0001
Reagents: a) Pd(PPh3)2CI2, TBAF, neat or THF; b) Pd(PPh3)2CI2, CuI, Et2NH; c) KOH, MeOH.
The acetylene derivatives of formula XXVII can in principle be prepared according to Scheme 14 via a Sonogashira type coupling of aryl halide XXIV and trimethylsilyl protected acetylene with subsequent hydrolysis of the trimethylsilyl protecting group.
Scheme 14
Figure imgf000051_0002
Reagents: a) Pd(PPh3)2CI2, TBAF, neat or THF; b) Pd(PPh3)2CI2, CuI, Et2NH; c) TBAF The acetylene derivatives of formula XXIII can in principle be prepared according to Scheme 15 via a Sonogashira type coupling of aryl halide XXVI and trimethylsilyl protected acetylene with subsequent hydrolysis of the trimethylsilyl protecting group.
Scheme 15
Figure imgf000052_0001
Reagents: a) Pd(PPh3)2CI2, TBAF, neat or THF; b) Pd(PPh3)2CI2, CuI, Et2NH; c) TBAF
The carboxylic acid derivatives of formula XXXII can in principle be prepared according to Scheme 16 via a Suzuki type coupling of boronic acid XXX or XXXIII with their corresponding aryl halides XXIV or XXVI with subsequent hydrolysis of the resulting carboxylic esters XXXI.
Scheme 16
Figure imgf000052_0002
Reagents: a) Pd(PPh3)4, Na2CO3, H2O, EtOH, toluene; b) KOH, MeOH. Compounds of formula XXXV can in principle be prepared according to Scheme 17 via a Sonogashira type coupling of acetylene XXIII and aryl halide XXXIV.
Scheme 17
Figure imgf000053_0001
Reagents: a) Pd(PPh3)2CI2, TBAF, neat or THF; b) Pd(PPh3)2CI2, CuI, Et2NH.
Compounds of formula XXXVI can in principle be prepared according to Scheme 18 via a Suzuki type coupling of boronic acid XXX and aryl halide XXXIV.
Scheme 18
Figure imgf000053_0002
Reagents: a) Pd(PPh3)4, Na2CO3, H2O, EtOH, toluene. Compounds of the general formula XXXIV can in principle be prepared as shown in Scheme 19 by an amide formation reaction between an amine Vl and a carboxylic acid XXXVII. The reagents typically used for the coupling are EDCI and HOBt.
Scheme 19
Figure imgf000054_0001
Reagents: a) Pd(PPh3)4, Na2CO3, H2O, EtOH, toluene.
The compounds according to the invention of the general formula I can be prepared as described below.
Abbreviations used:
ACN Acetonitrile
DIBAC Diisobutylaluminium hydride
DMF Λ/,Λ/-Dimethylformamide
EDC Λ/-Ethyl-Λ/'-(3-dimethylaminopropyl)carbodiimide
EtOH Ethanol
HATU O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
FMOC (9/-/-Fluoren-9-ylmethoxy)carbonyl
HOBt 1-Hydroxy-1H-benzotriazole
MeCN Acetonitrile
MeOH Methanol
MTBE Methyl tert-butyl ether
NMM 4-methylmorpholine
NMP N-Methylpyrrolidinone
Rf Reflux
RT Room temperature
TBAF Tetrabutylammonium fluoride
TFA Trifluoroacetic acid
THF Tetrahydrofuran
Synthesis of the compounds according to the invention
Example 1 5'-Fluoro-4-isopropoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1H-indol-3- ylmethyl)-ethyl]-amide} 3'-methylamide
Figure imgf000056_0001
1a) 5-lodo-2-isopropoxy-benzoic acid methyl ester A suspension of 5-lodo-2-hydroxy benzoic acid methyl ester (50 g), potassium carbonate (74,6 g) and /so-propyl iodide (89,9 ml) in acetone (500 ml) was stirred under reflux overnight. The reaction mixture was allowed to cool down to ambient temperature and the solid was removed by filtration. The filtrate was evaporated and the title compound was obtained in 96 % yield (55,1 g). 1H-NMR (CDCI3): 8.02 d (J = 2.3 Hz, 1 H); 7.67 dd (J = 2.5 Hz / 8.9 Hz, 1 H); 6.74 d (J = 8.9 Hz, 1 H); 4.54 m (1 H); 3.87 s (3H); 1.36 m (6H).
1 b) S'-Fluoro-4-isopropoxy-δ'-methylcarbamoyl-biphenyl-S-carboxylic acid methyl ester A solution of 5-lodo-2-isopropoxy-benzoic acid methyl ester (13.6 g), 3-Fluoro-5- methylcarbamoyl benzene boronic acid (9 g) and Pd(PPh3)4 (960 mg) in ethanol (150 ml_), toluene (200 ml.) and an aqueous sodium carbonate solution (2M, 45 ml.) were stirred at reflux for 4 h. The solvent was evaporated and the title compound was obtained as crude product in 17g yield. The compound was used without further purification in the next step. 1 c) S'-Fluoro-4-isopropoxy-S'-methylcarbamoyl-biphenyl-S-carboxylic acid A solution of S'-Fluoro-4-isopropoxy-S'-methylcarbamoyl-biphenyl-S-carboxylic acid methyl ester (2g), KOH (4 g) in methanol (30 ml.) was stirred at ambient temperature overnight. The solvent was distilled off under reduced pressure and the residue was extracted with water / ether. The water phase was acidified by addition of HCI (4N) and the precipitate filtered off. The title compound was obtained in 70% yield. 1H-NMR (CDCI3): 8.40 d (J = 2.5 Hz, 1 H); 7.77 dd (J = 2.5 Hz / 8.6 Hz, 1 H); 7.73 m (1 H); 7.47 m (1 H); 7.38 m (1 H); 7.14 d (J = 8.6 Hz, 1 H); 6.49 s (1 H); 4.93 m (1 H); 3.04 d (J = 4.8 Hz, 3H); 1.52 d (J = 6.1 Hz, 6H).
1 d) Toluene-4-sulfonic acid 3-(1 H-indol-3-yl)-2-(toluene-4-sulfonylamino)-propyl ester A solution of 2-Amino-3-(1 H-indol-3-yl)-propan-1-ol (1 Og) in pryridin (50 ml) was cooled to 00C and tosyl chloride (35 g) was added portionwise. The reaction mixture was al- lowed to warm to ambient temperature overnight and then poured into brine (100 ml). The mixture was filtrated, washed with dichloromethan and the layers of the filtrate were sepated. The aqueous phase was extracted with dichloromethane (3x) and the combined organic layer were washed with HCI (4x, 2N), brine (1x) and then dried over magnesium sulphate. The solvent was removed and the title compound was obtained in 92% yield. 1H-NMR (DMSO-d6): 10.68 s (1 H); 7.93 d (J = 7.4 Hz, 1 H); 7.59 d (J = 8.5 Hz, 2H); 7.40 d (J = 8.3 Hz, 2H); 7.35 d (J = 7.9 Hz, 2H); 7.23 d (J = 7.9 Hz, 1 H); 7.09 d (J = 8.1 Hz, 2H); 6.97 m (2H); 6.84 m (2H); 3.84 m (2H); 2.74 m (1 H); 2.69 m (1 H); 2.37 s (3H); 2.27 s (3H).
1 e) N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-4-methyl-benzenesulfonamide
A suspension of Toluene-4-sulfonic acid 3-(1 H-indol-3-yl)-2-(toluene-4-sulfonylamino)- propyl ester (24.05 g) and KCN (6.28 g) in MeOH (350 ml) was stirred under reflux for 5 hours, cooled to ambient temperature and diluted with ethyl acetate (400 ml) and brine (200 ml). The phases were separated and the organic layer was extracted with brine (6x70 ml). The organic layer was dried over magnesium sulphate and the solvent was removed under reduced pressure to yield the title compound in 88% yield. The product was used without further purification in the next step. 1H-NMR (DMSO-d6): 10.76 s (1 H); 8.10 s (1 H); 7.48 d (J = 8.3 Hz, 2H); 7.23 d (J = 8.1 Hz, 1 H); 7.14 d (J = 8.1 Hz, 2H); 7.04 m (3H); 6.83 m (1 H); 3.45 m (1 H); 2.72 m (2H); 2.61 m (1 H); 2.53 m (1 H); 2.28 s (3H). 1f) 3-Amino-4-(1 H-indol-3-yl)-butyronitrile
Liquid ammonia (ca. 350 ml) was condensed onto a solution of -[2-Cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-4-methyl-benzenesulfonamide (15.5 g) in anhydrous THF (115 ml) at - 78 0C. Sodium metal (ca. 4 g) was added in small portions until a deep turquoise colour persists, and the reaction mix was stirred for 30 min. at -78 0C. The reaction mixture was then quenched by addition of MeOH (72 ml) and then ammonium chloride (7.2 g) and the ammonia was allowed to evaporate in the fume cupboard. The residual solvents were removed in vacuo. The residue was partitioned between ethyl acetate and 2M HCI. The aqueous phase was basified (to pH 8) with 2M NH4OH, then extracted 3 times with ethyl acetate. Combined organics were washed (brine), dried (MgSO4) and reduced in vacuo to give the title compound as an orange foam (5.94 g). 1H-NMR (DMSO-d6): 10.87 s (1 H); 7.5O d (J = 7.7 Hz, 1 H); 7.31 d (J = 8.9 Hz, 1 H); 7.14 d (J = 2.3 Hz, 1 H); 7.03 m (1 H); 6.94 m (1 H); 3.21 m (1 H); 2.74 m (2H); 2.52 m (1 H); 2.40 m (1 H).
1 g) 5'-Fluoro-4-isopropoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide} 3'-methylamide
A solution of S'-Fluoro-4-isopropoxy-δ'-methylcarbamoyl-biphenyl-S-carboxylic acid (69 mg), 3-Amino-4-(1 H-indol-3-yl)-butyronitrile (50 mg), HOBt (34 mg) and EDCI (48 mg) in DMF (3 ml) was stirred overnight at ambient temperature. The reaction mixture was poured into water, extracted with ethyl acetate (3x). The combined organic layers were washed with brine and the solvent removed under vacuum. The title compound was obtained in 65 % yield after flash chromatography. 1H-NMR (CDCI3): 8.60 d (J = 7.9 Hz, 1 H); 8.45 d (J = 2.5 Hz, 1 H); 8.22 s (1 H); 7.73 m (3H); 7.38 m (3H); 7.18 m (4H); 7.05 d (J = 8.7 Hz, 1 H); 4.80 m (2H); 3.33 m (1 H); 3.20 m (1 H); 3.05 d (J = 4.9 Hz, 1 H); 2.89 m (1 H); 2.57 m (1 H); 1.44 m (6H).
Example 2
N-^-Cyano-i-tiH-indol-S-ylmethylJ-ethyll-S^-methylcarbamoyl-phenylethynyl)^-
Figure imgf000059_0001
2a) 3-Amino-4-(1 H-indol-3-yl)-butyronitrile
The title compound was prepared as described in example 1 d-1f.
2b) 5-Bromo-2-trifluoromethoxy-benzoic acid
Under argon a solution of LDA (12.45 ml, 2M in THF) was cooled to -78°C and a solution of 1-Bromo-4-trifluoromethoxy-benzene (3.7 ml) in THF (50 ml) was added slowly. The reaction mixture was stirred at -78°C for two hours and dry ice was added in excess. The solvent was distilled off and the crude product was dissolved in aqueous NaOH (1 N), extracted with dichloromethane, then acidified with HCI and again extracted with dichloromethane. The organic layers were dried over sodium sulphate and the solvent was removed in vacuum. The title compound was obtained in 49% yield. 1H-NMR (DMSO-d6): 13.78 s (1 H); 8.05 d (J = 2.6 Hz, 1 H); 7.92 dd (J = 2.6 Hz / 8.9 Hz, 1 H); 7.47 dd (J = 1.3 Hz / 8.9, 1 H).
2c) 5-Bromo-2-trifluoromethoxy-benzoic acid methyl ester
To a solution of 5-Bromo-2-trifluoromethoxy-benzoic acid (200 mg) in MeOH (2 ml) was added sulphuric acid (98%, 20μl) and the reaction was stirred under reflux overnight. The reaction was concentrated, then ethyl acetate (20 ml) was added. The organic phase was washed with brine (2x), dried over sodium sulphate and the solvent distilled off to yield 89% of the title compound. 1H-NMR (DMSO-d6): 8.08 d (J = 2.6 Hz, 1 H); 7.97 dd (J = 2.6 Hz / 8.7 Hz, 1 H); 7.52 m (1 H); 3.88 s (3H). 2d) 4-iodo-N-methylbenzenamide
41.2 g (0.166 mole) of 4-iodobenzoic acid was put in a flask, 28 ml of redistilled thionyl chloride and 30 ml of benzene was added, and mixture was heated gently for 5-6 hr. than SOCI2 and toluene was removed by the way of distillation. Hot residue was added with stirring to the mixture of a 10% aqueous sodium hydroxide, containing 7 g NaOH and 62 ml of 20% aqueous methylamine. The solution was stirred for 30 min, than it was cooled down with ice and the product was collected by filtration, washed with water, dried and crystallized from a water/ethanol (1 :1 ). Yield 85 %.
2e) N-Methyl-4-trimethylsilanylethynyl-benzamide
A mixture of 4-iodo-N-methylbenzenamide (26.1 g, 0.1 mole), 2.5 g of PdCI2(PPh3)2 (3,5%) and 1.6 g CuI (8%) in 200 ml of toluene was stirred for 30 min under argon. Than 1-ethynyl(trimethyl)silane (10 g, 0.102 mole) and Et3N (40.4 g, 0.4 mole) was added. This mixture was stirred for 2-3 hours under argon at r.t. Sub products were filtered off. The solvent was evaporated product was purified by flash chromatography with CHCI3. Chloroform was evaporated and product was crystallized from hexane. Yield - 17.65 g (75.7%)
2f) 4-Ethynyl-N-methyl-benzamide
17.65 g of N-methyl-4-[2-(1 ,1 ,1-trimethylsilyl)-1-ethynyl]benzamide (0.076 mole) was treated with 36 g of Bu4NF*H2O (0.1 15 mole) in 200 ml of THF at r.t. for 2 hours. The solvent was evaporated. Than the product was purified using flash chromatography (eluent CHCI3). Yield - 7.67 g (63%); ESI-MS [M+1]: 160.
2g) 5-(4-Methylcarbamoyl-phenylethynyl)-2-trifluoromethoxy-benzoic acid methyl ester: A suspension of 4-Ethynyl-N-methyl-benzamide (2.5 g), 5-Bromo-2-trifluoromethoxy- benzoic acid methyl ester (6.2 g), TBAF (1 M in THF, 47.1 ml), Pd(PPh3)2CI2 (551 mg) in THF (40 ml) and ethanol (25 ml) was stirred under reflux overnight. The solvent was distilled off under reduced pressure, ethyl acetate and water were added to the reaction and the phases were separated. The organic phase was dried over sodium sulphate and the solvent distilled off. The title compound was obtained in 30% yield after flash chromatography. 1H-NMR (DMSO-d6): 8.56 m (1 H); 8.10 d (J = 2.1 Hz, 1 H); 7.92 m (3H); 7.70 d (J = 8.3 Hz, 2H); 7.63 m (1 H); 3.89 s (3H); 2.80 d (J = 4.3 Hz, 3H). 2h) 5-(4-Methylcarbamoyl-phenylethynyl)-2-trifluoromethoxy-benzoic acid: 5-(4-Methylcarbamoyl-phenylethynyl)-2-trifluoromethoxy-benzoic acid methyl ester (1.78 g) and KOH (10% in MeOH, 28 ml.) in MeOH (28 ml.) were stirred at ambient temperature overnight. The solvent was distilled off under reduced pressure, the reac- tion mixture was diluted with water (200 ml.) and acidified with cone. HCI. The title compound was obtained in 91% yield after extraction with ethyl acetate and removal of the solvent. 1H-NMR (DMSO-d6): 13.67 s (1 H); 8.53 m (1 H); 8.03 d (J = 2.1 Hz, 1 H); 7.85 m (3H); 7.64 d (J = 8.3 Hz, 2H); 7.53 m (1 H); 2.76 d (J = 4.3 Hz, 3H).
2i) N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-5-(4-methylcarbamoyl-phenylethynyl)-2- trifluoromethoxy-benzamide
A solution of 5-(4-Methylcarbamoyl-phenylethynyl)-2-trifluoromethoxy-benzoic acid (100 mg), 3-Amino-4-(1 H-indol-3-yl)-butyronitrile (55 mg), HOBt x water (46 mg) and EDCI (58 mg) in DMF (5 ml) was stirred overnight at ambient temperature. The reaction mix- ture was poured into water, extracted with ethyl acetate (3x). The combined organic layers were washed with brine and the solvent removed under vacuum. The title compound was obtained in 25 % yield after flash chromatography. 1H-NMR (DMSO-d6): 10.90 s (1 H); 8.87 d (J = 8.1 Hz, 1 H); 8.53 m (1 H); 7.87 d (J = 8.7 Hz, 2H); 7.73 dd (J = 8.7 Hz / 2.3 Hz, 1 H); 7.64 d (J = 8.5 Hz, 2H); 7.57 d (J = 7.5 Hz, 1 H); 7.53 d (J = 2.1 Hz, 1 H); 7.49 m (1 H); 7.32 d (J = 7.9 Hz, 1 H); 7.20 d (J = 2.3 Hz, 1 H); 7.05 m (1 H); 6.97 m (1 H); 4.38 m (1 H); 2.98 m (2H); 2.78 m (1 H); 2.77 d (J = 4.3 Hz, 3H); 2.69 m (1 H).
The following compounds were obtained in analogy to the preparation methods described in detail:
Figure imgf000062_0001
Figure imgf000063_0002
Example 5
3'-Chloro-4-isopropoxy-biphenyl-3,4'-dicarboxylic acid 4'-amide 3-{[2-cyano-1 - (1 H-indol-3-ylmethyl)-ethyl]-amide}
Figure imgf000063_0001
5a) 5-lodo-2-isopropoxy-benzoic acid methyl ester 0 The title compound was prepared as described in example 1 a. 5b) 5-lodo-2-isopropoxy-benzoic acid
5-lodo-2-isopropoxy-benzoic acid methyl ester (1Og) and KOH (10% in MeOH, 30 mL) in MeOH (200 mL) were stirred at ambient temperature overnight. The reaction mixture was diluted with water (200 mL) and acidified with cone. HCI. The title compound was obtained in 97% yield after filtration of the precipitate and drying in vacuum. 1H-NMR (DMSO-d6): 12.77 s (1 H); 7.78 d (J = 2.3 Hz, 1 H); 7.70 dd (J = 2.3 Hz / 8.8 Hz, 1 H); 6.94 d (J = 8.8 Hz, 1 H); 4.59 m (1 H); 1.21 d (J = 6.1 Hz, 1 H).
5c) 3-Amino-4-(1 H-indol-3-yl)-butyronitrile The title compound was prepared as described in example 1 d-1f.
5d) N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-5-iodo-2-isopropoxy-benzamide 5-lodo-2-isopropoxy-benzoic acid (1.64 g), 3-Amino-4-(1 H-indol-3-yl)-butyronitrile (1.17 g), EDCI (1.23 g), HOBt (0.87 g) and triethylamine (1.11 mL) in DMF (20 mL) were stirred at ambient temperature for 48 hours. The reaction mixture was poured into water, extracted with ethyl acetate (3x). The combined organic layers were washed with brine and the solvent removed under vacuum. The title compound was obtained in 54 % yield after flash chromatography. 1H-NMR (DMSO-d6): 10.89 s (1 H); 8.31 d (J = 8.3 Hz, 1 H); 7.88 d (J = 2.5 Hz, 1 H); 7.69 dd (J = 8.7 Hz / 2.5 Hz, 1 H); 7.54 d (J = 7.7 Hz, 1 H); 7.31 d (J = 7.9 Hz, 1 H); 7.16 d (J = 2.3 Hz, 1 H); 7.04 m (1 H); 6.95 m (2H); 4.67 m (1 H); 4.50 m (1 H); 3.00 m (2H); 2.84 m (1 H); 2.71 m (1 H); 1.18 m (6H).
5e) 3'-Chloro-4-isopropoxy-biphenyl-3,4'-dicarboxylic acid 4'-amide 3-{[2-cyano-1-(1 H- indol-3-ylmethyl)-ethyl]-amide} A solution of N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]- 5-iodo-2-isopropoxy-benzamide
5-lodo-2-isopropoxy-benzoic acid (100 mg), 3-Chloro-4-carbamoyl benzene boronic acid (41 mg) and Pd(PPh3)4 (12 mg) in ethanol (0.5 mL), toluene (1.5 mL) and an aqueous sodium carbonate solution (2M, 0.31 mL) were heated in a microwave reactor for 20 minutes at 1200C. The solvent was evaporated and after flash chromatography the title compound was obtained in 48% yield. 1H-NMR (DMSO-d6): 10.90 s (1 H); 8.39 d (J = 8.1 Hz, 1 H); 7.97 d (J = 2.6 Hz, 1 H); 7.86 s (1 H); 7.80 dd (J = 8.7 Hz / 2.6 Hz, 1 H); 7.68 d (J = 1.7 Hz, 1 H); 7.57 m (3H); 7.48 d (J = 8.1 Hz, 1 H); 7.32 d (J = 8.1 Hz, 1 H); 7.23 d (J = 8.7 Hz, 1 H); 7.18 d (J = 2.3 Hz, 1 H); 7.04 m (1 H); 6.95 m (1 H); 4.78 m (1 H); 4.54 m (1 H); 3.04 m (2H); 3.01 m (1 H); 2.74 m (1 H); 1.23 m (6H). The following compounds were obtained in analogy to the preparation methods described in detail:
Figure imgf000065_0001
Example 8
5-(4-Carbamoyl-phenylethynyl)-N-[2-cyano-1-(1H-indol-3-ylmethyl)-ethyl]-2- isopropoxy-benzamide
Figure imgf000066_0001
8a) N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-5-iodo-2-isopropoxy-benzamide The title compound was prepared as described in examples 5a-5b.
8b) 4-Ethynyl-benzamide
The title compound was prepared in analogy to the examples 2d-2f.
8c) 5-(4-Carbamoyl-phenylethynyl)-N-[2-cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2- isopropoxy-benzamide
A mixture of N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-iodo-2-isopropoxy-benzamide (100 mg), 4-Ethynyl-benzamide (30 mg), Pd(PPh3)2CI2 (7.2 mg), TBAF (0.62 ml, 1 M in THF) in THF (2 ml) and ethanol (0.5 ml) was heated in a microwave oven at 1 100C for 20 minutes. The reaction mixture was diluted with ethyl acetate and extracted with water. The solvent of the organic layer was removed under reduced pressure and the title compound was obtained after flash chromatography in 33% yield. 1H-NMR (DMSO-d6): 10.90 s (1 H); 8.34 d (J = 8.1 Hz, 1 H); 8.02 s (1 H); 7.87 d (J = 8.1 Hz, 2H); 7.80 d (J = 2.3 Hz, 1 H); 7.60 m (4H); 7.42 s (1 H); 7.32 d (J = 8.1 Hz, 1 H); 7.19 m (2H); 7.05 m (1 H); 6.96 m (1 H); 4.77 m (1 H); 4.52 m (1 H); 3.01 m (2H); 2.86 m (1 H); 2.75 m (1 H); 1.22 m (6H). The following compounds were obtained in analogy to the preparation methods de- scribed in detail:
Figure imgf000067_0001
Figure imgf000068_0002
Example 12
4'-Morpholin-4-yl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1 -(1 H- indol-3-ylmethyl)-ethyl]-amide
Figure imgf000068_0001
12a) 5-Bromo-2-trifluoromethoxy-benzoic acid The title compound was prepared as described in example 2b.
12b) 3-Amino-4-(1 H-indol-3-yl)-butyronitrile The title compound was prepared as described in examples 1 d-1f.
12c) N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-5-bromo-2-trifluoromethoxy-benzamide A solution of 5-Bromo-2-trifluoromethoxy-benzoic acid (2.5 g), 3-Amino-4-(1 H-indol-3- yl)-butyronitrile (1.75 g), HOBt x water (1.48 g) and EDCI (1.85 g) in DMF (20 ml) was stirred overnight at ambient temperature. The reaction mixture was poured into water, extracted with ethyl acetate (3x). The combined organic layers were washed with brine and the solvent removed under vacuum. The title compound was obtained in 46 % yield after flash chromatography. 1H-NMR (DMSO-d6): 10.89 s (1 H); 8.87 d (J = 7.9 Hz, 1 H); 7.76 dd (J = 2.5 Hz / 8.7 Hz, 1 H); 7.56 d (J = 7.9 Hz, 1 H); 7.50 d (J = 2.6 Hz, 1 H); 7.39 dd (J = 1.5 Hz / 8.9 Hz, 1 H); 7.32 d (J = 8.1 Hz, 1 H); 7.18 d (J = 2.3 Hz, 1 H); 7.05 m (1 H); 6.97 m (1 H); 4.35 m (1 H); 2.97 m (2H); 2.78 m (1 H); 2.68 m (1 H).
12d) 4'-Morpholin-4-yl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H- indol-3-ylmethyl)-ethyl]-amide To 0.1 mmol of N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-bromo-2-trifluoromethoxy- benzamide (0.2 M in THF) in a microwave vessel are added 1.5 eq of 4-Morpholin-4-yl- benzene boronic acid (0.4 M in THF), 3 eq of K2CO3 (1 M in H2O), 0.1 eq Pd(OAc)2 (0.0375 M in THF), 0.2 eq Tri(o-tolylphosphin) (0.5 M in THF) and 100 μl of H2O. The mixture is heated to 1300C under stirring in a microwave oven for 1 h. After cooling, the solution is evaporated, redissolved in DMSO, filtered and subjected to preparative
HPLC chromatography. HPLC purification: Machine: Analytical 4 channel MUX system with CTC Pal injector, Waters 1525 Pumps, Waters 2488 UV detector and Waters ZQ 2000 single quad MS detector. Column Purospher Star RP C18 4.6x125 5μm; detection wavelength 214 nm; flow rate 2 ml/min; eluents A): 0.1 % TFA in H2O, B): 0.1 % TFA in ACN; gradients based on B: 1% to 99% (5') to 99% (1 ') to 1% (0.25') to 1 % (1.75'). Molecular peak (ESI, M+1 ): 550, retention time: 4.07 min. The following compounds were obtained in analogy to the preparation methods described in detail:
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
The present invention further relates to the aryl halides of the formulae XIII, XIV or XVI as intermediates of the process according to the invention for preparing the compounds according to the invention, namely:
N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-iodo-2-isopropoxy-benzamide;
N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-bromo-2-trifluoromethoxy-benzamide.

Claims

Claims
1. Compounds of the formula
Figure imgf000100_0001
in which R1 is hydrogen, fluorine or d-C6-alkyl; where the hydrocarbon chains therein may optionally be substituted one or more times by fluorine;
R2 is hydrogen, halogen, nitro, amino, cyano, d-C6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl, C3-C7-cycloalkyl, hydroxy-d-C6-alkylene, hydroxy-C3- C6-alkenylene, hydroxy-C3-C6-alkynylene, d-C6-alkyloxy, C1-C6- alkyloxy-Ci-C6-alkylene, C3-C7-cycloalkyloxy, C3-C7-cycloalkyl-d-C6- alkylenoxy, C3-C7-cycloalkyloxy-Ci-C6-alkylene, d-C6-alkyloxy-C3-C6- alkenylene, d-Ce-alkyloxy-Cs-Cβ-alkynylene, Ci-C6-alkylamino-Ci-C6- alkylene, di(Ci-C6-alkyl)amino-Ci-C6-alkylene; where the hydrocarbon chains therein may optionally be substituted one or more times by fluorine, cyano or hydroxy;
R3, R4, R5 may be independently of one another hydrogen, hydroxy, halogen, nitro, amino, cyano, phenyl, d-C6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl, C3- C7-cycloalkyl, C3-C7-cycloalkyl-d-C6-alkylene, C3-C7-heterocycloalkyl, where the hydrocarbon chains therein may optionally be substituted one or more times by fluorine, cyano or the radicals:
Figure imgf000101_0001
Figure imgf000101_0002
or independently of one another hydroxy-Ci-C6-alkylene, hydroxy-C3-C6- alkenylene, hydroxy-C3-C6-alkynylene, Ci-C6-alkyloxy, C3-C7- cycloalkyloxy, C3-C7-cycloalkyl-Ci-C6-alkylenoxy, Ci-C6-alkyloxy-Ci-C6- alkylene, C3-C7-cycloalkyloxy-Ci-C6-alkylene, Ci-C6-alkyloxy-C3-C6- alkenylene, d-Ce-alkyloxy-Cs-Cβ-alkynylene, Ci-C6-alkyloxyphenyl-Ci- C6-alkylene, phenyloxy-Ci-C6-alkylene, Ci-C6-alkylamino, di(Ci-C6-alkyl)amino, Ci-C6-alkylamino-Ci-C6- alkylene, di(Ci-C6)-alkylamino-Ci-C6-alkylene, C3-C7-cycloalkyl-(C0-C6- alkyl)amino,
C1-C6-acyl-(Co-C6-alkyl)amido, Ci-Ce-alkylaminocarbonyl, di(C1-C6- alkyl)aminocarbonyl, (C3-C7-cycloalkyl)aminocarbonyl, di(C3-C7- cycloalky^aminocarbonyl, C3-C7-cycloalkyl-C1-C6-alkyleneamino- carbonyl,
Ci-C6-alkylcarbonyl, C3-C7-cycloalkylcarbonyl, carboxy, carboxamido [-C(O)NH2], Ci-Cβ-alkyloxycarbonyl, Ci-C3-alkylsulphanyl, d-C6-alkysulphonyl, C3-C7-cycloalkylsulphonyl, C3-C7-cycloalkyl-Ci-C6-alkylenesulphonyl,
Ci-C6-alkylaminosulphonyl, di(Ci-C6-alkyl)aminosulphonyl, (C3-C7- cycloalkyl)aminosulphonyl, di(C3-C7-cycloalkyl)aminosulphonyl, C3-C7- cycloalkyl-Ci-C6-alkyleneaminosulphonyl, d-C6-alkylsulphonylamido, -N(C0-C6-alkyl)-C(O)-Ci-C6-alkyl, -N(C0-C6-alkyl)-C(O)-C3-C7-cycloalkyl, -N(Co-C6-alkyl)-C(0)-N-di(Co-C6-alkyl), -N(C0-C6-alkyl)-C(O)-O-(C0-
C6)alkyl, -N(C0-C6-alkyl)-C(O)-NH-C3-C7-cycloalkyl, -N(Co-C6-alkyl)-Sθ2-Ci-C6-alkyl, -N(C0-C6-alkyl)-SO2-C3-C7-cycloalkyl, -N(C0-C6-alkyl)-S02-N-di(Co-C6-alkyl), -N(C0-C6-alkyl)-SO2-NH-(C3-C7)- cycloalkyl, -CCOJ-NCHJ-Cz-Cβ-alkylene-CCi-Cβ-alkyOamine, -C(O)-N(H)-C2-C6- alkylene-[di(C1-C6-alkyl)]amine, -C(O)-N(H)-C2-C6-alkylene-(C3-C7- cycloalkyl)amine, -C(O)-N(H)-C2-C6-alkylene-(C3-C7-cycloalkyl-C1-C6- alkyl)amine, -S(O2)-N(H)-C2-C6-alkylene-(Ci-C6-alkyl)amine, -S(O2)-N(H)-C2-C6- alkylene-[di(Ci-C6-alkyl)]amine, -S(O2)-N(H)-C2-C6-alkylene-(C3-C7- cycloalkyl)amine, -S(O2)-N(H)-C2-C6-alkylene-(C3-C7-cycloalkyl-CrC6- alkylene)amine,
-O-C2-C6-alkylene-(Ci-C6-alkyl)amine, -O-C2-C6-alkylene-[di(Ci-C6- alkylene)]amine,
(Ci-C6-alkyl)oxy-C2-C6-alkylene-aminocarbonyl, carboxy-Ci-Ce-alkylene-carbonylamido, (Ci-C6-alkyl)sulfonylmido, or the radicals:
Figure imgf000102_0001
Figure imgf000103_0001
R3 and R4 may together form heterocycloalkyl, cycloalkyl;
Q is an aryl or heteroaryl group or the group
Figure imgf000104_0001
in which A is a monocyclic aryl or a monocyclic heteroaryl group;
V is a cycloalkylen, cycloalkenylen, heterocycloalkylen or heterocycloalkenylen group;
X is a bond or an ethinylen group; W is an aryl or heteroaryl group;
where
R1 substitutes one or more positions of the aryl or heteroaryl ring in the indole residue;
R2 substitutes one or more positions of the aryl or heteroaryl ring in the radical Q and or the radical V.
2. Compounds according to claim 1 , namely cyanomethyl substituted N-acyl tryp- tamines of the formula Il
Figure imgf000105_0001
in which the radicals R1 to R5, X and W have the same meaning as defined in claim 1.
3. Compounds according to claim 1 , namely cyanomethyl substituted N-acyl tryp- tamines of the formula III
Figure imgf000105_0002
in which the radicals R1 to R5, X, W and V have the same meaning as defined in claim 1.
4. Compounds according to claim 1 or 2, namely cyanomethyl substituted N-acyl tryptamines of the formula IV
Figure imgf000106_0001
in which the radicals R1 to R5, X and W have the same meaning as defined in claim 1.
5. Compounds according to claim 1 or 3, namely cyanomethyl substituted N-acyl tryptamines of the formula V
Figure imgf000106_0002
in which the radicals R1 to R5, X, W and V have the same meaning as defined in claim 1.
6. Compounds according to any of the preceding claims, namely
1 5'-Fluoro-4-isopropoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 3'-methylamide;
2 N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-5-(4-methylcarbamoyl-phenylethynyl)-2- trifluoromethoxy-benzamide;
3 3'-Chloro-4-isopropoxy-biphenyl-3,4'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 4'-methylamide;
4 5-(4-Carbamoyl-2-methylphenylethynyl)-N-[2-cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2- trifluoromethoxy-benzamide;
5 3'-Chloro-4-isopropoxy-biphenyl-3,4'-dicarboxylic acid 4'-amide 3-{[2-cyano-1-(1 H- indol-3-ylmethyl)-ethyl]-amide};
6 3'-Chloro-4-isopropoxy-4'-(morpholine-4-carbonyl)-biphenyl-3-carboxylic acid [2- cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-amide;
7 4-lsopropoxy-3',4'-dimethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
8 5-(4-Carbamoyl-phenylethynyl)-N-[2-cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2-isoprop- oxy-benzamide g N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2-isopropoxy-5-(4-methylcarbamoyl-phenyl- ethynyl)-benzamide;
I o N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2-isopropoxy-5-(3-methylcarbamoyl-phenyl- ethynyl)-benzamide;
I 1 N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2-isopropoxy-5-(2-methylcarbamoyl-phenyl- ethynyl)-benzamide;
12 4'-Morpholin-4-yl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide 4'-Methanesulfonylamino-methyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2- cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-amide;
N-{3'-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethylcarbamoyl]-4'-trifluoromethoxy-biphenyl- 3-ylJ-succinamic acid;
4'-(Pyrrolidine-1-carbonyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1- (1 H-indol-3-ylmethyl)-ethyl]-amide;
N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-(1-methyl-1 H-indol-5-yl)-2- trifluoromethoxy-benzamide;
4-Trifluoromethoxy-biphenyl-3,4'-dicarboxylic acid 3-{[2-cyano-1 -(1 H-indol-3-yl- methyl)-ethyl]-amide} 4'-[(2-methoxy-ethyl)-amide];
3'-(Pyrrolidine-1-carbonyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1- (1 H-indol-3-ylmethyl)-ethyl]-amide;
4-Trifluoromethoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 3'-ethylamide;
4-Trifluoromethoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 3'-(isobutyl-amide);
4-Trifluoromethoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 3'-cyclopentylamide;
3'-(Methanesulfonylamino-methyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2- cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-amide;
4'-(Acetylamino-methyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H- indol-3-ylmethyl)-ethyl]-amide;
3'-(Acetylamino-methyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H- indol-3-ylmethyl)-ethyl]-amide;
4'-Methylsulfamoyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H- indol-3-ylmethyl)-ethyl]-amide; 3-Chloro-3'-[2-cyano-1 -(1 H-indol-3-ylmethyl)-ethylcarbamoyl]-4'-trifluoromethoxy- biphenyl-4-carboxylic acid methyl ester;
4'-Ethylsulfamoyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide;
S'-Chloro-4-trifluoromethoxy-biphenyl-S^'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide} 4'-isopropylamide;
S'-Chloro-4-trifluoromethoxy-biphenyl-S^'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide} 4'-cyclopropylamide;
S'-Chloro-4-trifluoromethoxy-biphenyl-S^'-dicarboxylic acid 4'-tert-butylamide 3-{[2- cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-amide};
S'-Chloro-4-trifluoromethoxy-biphenyl-S^'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide} 4'-dimethylamide;
S'-Chloro-4-trifluoromethoxy-biphenyl-S^'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide} 4'-diethylamide;
3'-Chloro-4'-(morpholine-4-carbonyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2- cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-amide;
3'-Chloro-4'-(piperidine-1-carbonyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2- cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-amide;
3'-Chloro-4'-(pyrrolidine-1-carbonyl)-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2- cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-amide;
5'-Ethoxy-3'-fluoro-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide;
5'-Fluoro-4-trifluoromethoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide} 3'-methylamide;
3'-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethylcarbamoyl]-3-methoxy-4'-trifluoromethoxy- biphenyl-4-carboxylic acid methyl ester; S'-Fluoro-δ'-methoxy-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H- indol-3-ylmethyl)-ethyl]-amide;
4'-Acetylamino-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide;
N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-5-quinolin-3-yl-2-trifluoromethoxy- benzamide;
3',5'-Dimethyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide;
4-Trifluoromethoxy-biphenyl-3,3'-dicarboxylic acid 3'-amide 3-{[2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide};
S'-Cyano-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
5-Benzo[1 ,3]dioxol-5-yl-N-[2-cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-2-trifluoromethoxy- benzamide;
S'-Acetylamino-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide;
S'-Methanesulfonylamino-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1- (1 H-indol-3-ylmethyl)-ethyl]-amide;
4'-Chloro-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
2'-Methyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
2'-Fluoro-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
4-Trifluoromethoxy-biphenyl-3,3'-dicarboxylic acid 3-{[2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide} 3'-methylamide; N-[2-Cyano-1 -(1 H-indol-3-ylmethyl)-ethyl]-5-quinolin-6-yl-2-trifluoromethoxy- benzamide;
S'-Hydroxy-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H-indol-3- ylmethyl)-ethyl]-amide;
4-Trifluoromethoxy-4'-trifluoromethyl-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide;
S'-HydroxymethyM-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide;
4-Trifluoromethoxy-[1 ,1 ';3',1 "]terphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
3'-Fluoro-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
S'-Acetyl-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
3'-Amino-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
4'-Acetyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
4'-Methylsulfanyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide;
4-Trifluoromethoxy-3'-trifluoromethyl-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol- 3-ylmethyl)-ethyl]-amide;
4'-Hydroxy-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-naphthalen-1-yl-2-trifluoromethoxy- benzamide; 4'-Methyl-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
S'-Chloro-4-trifluoromethoxy-biphenyl-S-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-naphthalen-2-yl-2-trifluoromethoxy- benzamide;
3'-Methoxy-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
4'-Methoxy-4-trifluoromethoxy-biphenyl-3-carboxylic acid [2-cyano-1-(1 H-indol-3-yl- methyl)-ethyl]-amide;
N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-thiophen-3-yl-2-trifluoromethoxy- benzamide.
7. Process for preparing compounds of the formula I of claim 1 , wherein an amine of the formula Vl
Figure imgf000112_0001
in which the radical R1 has the same meaning as defined in claim 1 , is coupled with a carboxylic acid of the formula VII
Figure imgf000113_0001
in which R2, R3, R4, R5, Q, X and W have the same meaning as defined in claim 1 , in an amide forming reaction comprising
a) conversion of said carboxylic acids into an intermediate active ester or car- bonyl chloride with a suitable peptide-coupling reagent, or with thionyl chloride, oxalyl chloride, phosgene or derivatives thereof, where appropriate in the presence of a base, b) reacting the active intermediate resulting from step a) with said amino alcohol.
Process according to claim 7 for preparing compounds of the formula Il of claim 2, wherein an amine of the formula Vl is coupled with a carboxylic acid of the formula VIII
Figure imgf000113_0002
in which R2, R3, R4, R5, X and W have the same meaning as defined in claim 2.
9. Process according to claim 7 for preparing compounds of the formula III of claim 3, wherein an amine of the formula Vl is coupled with a carboxylic acid of the formula IX
Figure imgf000114_0001
in which R2, R3, R4, R5, X, V and W have the same meaning as defined in claim 3.
10. Process according to claim 7 for preparing compounds of the formula IV of claim 4, wherein an amine of the formula Vl is coupled with a carboxylic acid of the formula X
Figure imgf000114_0002
in which R2, R3, R4, R5, X and W have the same meaning as defined in claim 4.
11. Process according to claim 7 for preparing compounds of the formula V of claim 5, wherein an amine of the formula Vl is coupled with a carboxylic acid of the formula Xl
Figure imgf000115_0001
in which R2, R3, R4, R5, X, V and W have the same meaning as defined in claim 5.
12. Process for preparing compounds of the formula I of claim 1 , wherein the building block of the formula XII
Figure imgf000115_0002
in which R3, R4, R5, W and X have the same meaning as defined in claim 1 and
R is a -B(OH)2, -C≡C-H, -Zn-HaI or -Sn(alkyl)3) group, is coupled in a metal catalyzed cross-coupling reaction with an aryl halide of the formula XIII
Figure imgf000116_0001
in which R1 , R2 and Q have the same meaning as defined in claim 1 , and
Hal stands for a chlorine, bromine or iodine.
13. Process according to claim 12 for preparing compounds of the formula Il of claim 2, wherein the building block of the formula XII is coupled with an aryl halide of the formula XIV
Figure imgf000116_0002
in which R1 and R2 have the same meaning as defined in claim 1 , and
Hal stands for a chlorine, bromine or iodine.
14. Process according to claim 12 for preparing compounds of the formula III of claim 3, wherein the building block of the formula XII is coupled with an aryl hal- ide of the formula XV
Figure imgf000117_0001
in which R1 , R2 and V have the same meaning as defined in claim 1 , and
Hal stands for a chlorine, bromine or iodine.
15. Process according to claim 12 for preparing compounds of the formula IV of claim 4, wherein the building block of the formula XII is coupled with an aryl hal- ide of the formula XVI
Figure imgf000117_0002
in which R1 and R2 have the same meaning as defined in claim 1 , and
Hal stands for a chlorine, bromine or iodine.
16. Process according to claim 12 for preparing compounds of the formula V of claim 5, wherein the building block of the formula XII is coupled with an aryl hal- ide of the formula XVII
Figure imgf000118_0001
in which R1 , R2 and V have the same meaning as defined in claim 1 , and
Hal stands for a chlorine, bromine or iodine.
17. Aryl halides as intermediates in a process according to any of claims 12 to 16, namely:
N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-iodo-2-isopropoxy-benzamide;
N-[2-Cyano-1-(1 H-indol-3-ylmethyl)-ethyl]-5-bromo-2-trifluoromethoxy- benzamide.
18. Pharmaceutical compositions comprising at least one of the compounds accord- ing to any of claims 1 to 6 with pharmaceutically suitable excipients and/or carriers.
19. Use of the compounds of the general formula I according to any of claims 1 to 6 for the fertility control in men or in women.
20. Process for producing medicaments comprising at least one of the compounds of the general formula I according to any of claims 1 to 6 for the prevention and/or treatment of osteoporosis.
PCT/EP2008/060123 2007-08-01 2008-08-01 Cyanomethyl substituted n-acyl tryptamines WO2009016253A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07075662A EP2020404A1 (en) 2007-08-01 2007-08-01 Cyanomethyl substituted N-Acyl Tryptamines
EP07075662.2 2007-08-01

Publications (2)

Publication Number Publication Date
WO2009016253A2 true WO2009016253A2 (en) 2009-02-05
WO2009016253A3 WO2009016253A3 (en) 2009-03-26

Family

ID=38786885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/060123 WO2009016253A2 (en) 2007-08-01 2008-08-01 Cyanomethyl substituted n-acyl tryptamines

Country Status (3)

Country Link
US (1) US20090069321A1 (en)
EP (1) EP2020404A1 (en)
WO (1) WO2009016253A2 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2019054427A1 (en) 2017-09-14 2019-03-21 第一三共株式会社 Compound having cyclic structure
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458161B1 (en) 2011-11-03 2016-10-04 Vanderblit University TSPO ligands for cancer imaging and treatment
TWI458732B (en) * 2012-06-27 2014-11-01 Univ Nat Chiao Tung Borate moiety-contained linker and bio-sensing element containing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081011A1 (en) * 2003-03-14 2004-09-23 Avidex Limited Immunomodulating heterocyclic compounds
WO2007017289A2 (en) * 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081011A1 (en) * 2003-03-14 2004-09-23 Avidex Limited Immunomodulating heterocyclic compounds
WO2007017289A2 (en) * 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10813930B2 (en) 2010-12-22 2020-10-27 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10213427B2 (en) 2010-12-22 2019-02-26 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11840534B2 (en) 2012-06-13 2023-12-12 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US10131667B2 (en) 2012-06-13 2018-11-20 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US9745311B2 (en) 2012-08-10 2017-08-29 Incyte Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10450313B2 (en) 2013-04-19 2019-10-22 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10947230B2 (en) 2013-04-19 2021-03-16 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US10040790B2 (en) 2013-04-19 2018-08-07 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10738048B2 (en) 2015-02-20 2020-08-11 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10632126B2 (en) 2015-02-20 2020-04-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en) 2015-02-20 2023-06-06 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10214528B2 (en) 2015-02-20 2019-02-26 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10016438B2 (en) 2015-02-20 2018-07-10 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9801889B2 (en) 2015-02-20 2017-10-31 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10251892B2 (en) 2015-02-20 2019-04-09 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
WO2019054427A1 (en) 2017-09-14 2019-03-21 第一三共株式会社 Compound having cyclic structure
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Also Published As

Publication number Publication date
US20090069321A1 (en) 2009-03-12
EP2020404A1 (en) 2009-02-04
WO2009016253A3 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
WO2009016253A2 (en) Cyanomethyl substituted n-acyl tryptamines
US20080287493A1 (en) Arylmethylen substituted n-acyl-y-aminoalcohols
WO2009013354A1 (en) ARYLMETHYLENE SUBSTITUTED N-ACYL-β-AMINO ALCOHOLS
WO2008071455A1 (en) Bicyclic acyltryptophanols
JP2009504597A (en) Acyltryptophanol
US20070060573A1 (en) Acyltryptophanols
KR101612971B1 (en) Amide compound
JP4623483B2 (en) Pyrrotriazine derivative having sPLA2 inhibitory action
NO302522B1 (en) 4-pyrimidinyl and pyridinyl derivatives of indolyl-3-yl-alkylpiperazine and pharmaceutical compositions containing such a compound
WO2008071453A1 (en) 1,2-diarylacetylene derivatives of acyltryptophanols
US20140357655A1 (en) Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists
AU600813B2 (en) Aliphatic carboxamides
WO2008116671A1 (en) 2,3,4,9-tetrahydro-1h-carbazoles
US6831095B1 (en) Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
EP1956016A1 (en) Bicyclic acyltryptophanols
EP1932831A1 (en) 1,2-Diarylacetylene Derivatives of Acyltryptophanols
US20080275083A1 (en) 2,3,4,9-tetrahydro-1h-carbazoles
US20090075987A1 (en) Alkylacetylene substituted acyltryptophanols
WO2009021980A1 (en) α-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS
US20080255117A1 (en) Sulfonyltryptophanols
US20080207728A1 (en) Bicyclic acyltryptophanols
WO2008104597A2 (en) Sulfonyltryptophanols
JP2002510675A (en) N-aryloxyethyl-indolyl-alkylamines for treatment of depression (5-HT1A receptor activators)
DE102005038632B4 (en) Acyltryptophanole
EP1220839B1 (en) Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08786743

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08786743

Country of ref document: EP

Kind code of ref document: A2